Topical treatment of immune checkpoint inhibitor induced diarrhoea, colitis or enterocolitis using antibodies and fragments thereof
Patent Information
- Application Number
- JP2024084405
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2018-12-07
- Filing Date
- 2024-05-23
- Publication Date
- 2024-11-12
AI Technical Summary
Current treatments for immune checkpoint inhibitor-induced diarrhea, colitis, and enterocolitis require systemic administration of immunosuppressants, which disrupt cancer treatment and have adverse side effects, necessitating the development of a localized treatment approach.
Topical administration of TNFα-specific antibodies or functional fragments in the gastrointestinal tract to treat or prevent immune-related adverse events without disrupting systemic cancer treatment.
Minimizes systemic side effects and allows continued cancer treatment by targeting immune-related adverse events locally, preventing progression and recurrence of gastrointestinal issues.
Smart Images

Figure 00000039_0000 
Figure 00000039_0001 
Figure 00000039_0002
Abstract
Description
FIELD OF THEINVENTION
[0001] The present invention relates to the use of compositions comprising antibody molecules, functional fragments and derivatives specific for tumor necrosis factor alpha (TNFα) in the localized treatment of at least one adverse event of the gastrointestinal tract induced by cancer therapy in a patient, preferably induced by one or more immune checkpoint (ICP) inhibitors. In particular, the present invention relates to the therapeutic use of such compositions in the localized treatment of immune checkpoint (ICP) inhibitor-induced diarrhea, colitis and / or enteritis, especially in patients who have not stopped taking ICP inhibitors as cancer therapy, as well as the use of such compositions as at least partial prevention or treatment of ICP inhibitor-induced diarrhea, colitis and / or enteritis in patients undergoing treatment with an ICP inhibitor. Background
[0002] In recent years, the use of inhibitors that target so-called immune checkpoints (ICPs) and thereby activate the immune system against cancer cells has emerged as a promising new cancer treatment strategy.
[0003] ICP inhibitors, which are immune stimulants that "uninhibit" existing immune responses or do not inhibit the initiation of immune responses, have been shown to be highly effective in treating certain types of cancer. In the search for ICP inhibitors, the ICP members that have received the most attention in recent years are programmed death-1 (PD-1), programmed death-ligand 1 (PD-L1), and cytotoxic T-lymphocyte-associated protein-4 (CTLA-4). For example, PD-1, PD-L1, and CTLA-4 inhibitors have shown great potential to improve the overall survival of patients with malignant melanoma, malignant non-small cell lung cancer, head and neck squamous cell carcinoma, and renal cell carcinoma (Wang et al., Inflamm Bowel Dis, 24(8):1695-1705, July 2018). Furthermore, in patients with malignant lymphoma, ICP inhibitors have shown promising results in phase I and II clinical trials, and the PD-1 inhibitor nivolumab was approved by the Food and Drug Administration in May 2016 for the treatment of relapsed or refractory classical Hodgkin lymphoma (Hude et al., Haematologica, January 2017, 102(1):30-42).
[0004] CTLA-4, PD-1, and their ligands are members of the B7-CD28 family of co-signaling molecules that play important roles at all stages of T cell function and other cell functions. The PD-1 receptor is expressed on the surface of activated T cells (and B cells) and, under normal circumstances, binds to ligands (PD-L1 and PD-L2) expressed on the surface of antigen-presenting cells such as dendritic cells and macrophages. This interaction sends a signal to the T cell to essentially turn it off or inhibit it.
[0005] Currently, available ICP inhibitors that target pathways that inhibit the activation, proliferation, and function of cytotoxic T cells include antibodies specific for CTLA-4, PD-1, and PD-L1. For example, monoclonal antibodies targeting either PD-1 or PD-L1 can block this binding and enhance the immune response against cancer cells. These inhibitors have shown great promise for the treatment of various types of cancer.
[0006] Although the enhancement of a patient's intrinsic adaptive immune system by ICP inhibitors leads to improved tumor control, nonspecific immune activation often results in the development of immune-related adverse events affecting various organ systems, particularly the gastrointestinal (GI) tract, such as ICP inhibitor-induced colitis, enteritis, and / or diarrhea. Indeed, clinical trial results indicate that the most common severe or life-threatening (grade 3 and 4) immune-related adverse events occur in the gastrointestinal tract (Wang et al., Inflamm Bowel Dis, 24(8):1695-1705, July 2018; Wang DY et al., "Fatal Toxic Effects Associated with Immune Checkpoint Inhibitors," Review and Metabolic Analysis, JAMA Oncol. Published online September 13, 2018, doi:10.1001 / jamaoncol.2018.3923).
[0007] For example, immune-related adverse events associated with the gastrointestinal tract, such as ICP inhibitor-induced colitis, have been reported in approximately 21%-44% of patients treated with CTLA-4 inhibitors and somewhat less frequently in patients treated with PD-1 / PD-L1 inhibitors (Wang et al., Inflamm Bowel Dis, 24(8):1695-1705, July 2018).
[0008] Colitis is a disorder characterized by inflammation of the large intestine / colon. Enteritis is defined as a disorder characterized by inflammation of the small intestine. Enteritis is a disorder characterized by inflammation of both the small intestine and the large intestine / colon, i.e., a combination of enteritis and colitis. Symptoms that characterize ICP inhibitor-induced colitis include diarrhea, abdominal pain, nausea, cramps, blood or mucus in the stool, changes in bowel habits, fever, abdominal distension, constipation, and constipation (Brahmer et al., "Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology (ASCO) Practice Guideline, J Clin Oncol. 2018 Jun, 10;36(17):1714-1768). Symptoms that characterize ICP inhibitor-induced colitis include those listed above for ICP inhibitor-induced colitis.
[0009] As described in the ASCO Clinical Practice Guideline for the Management of Immune-Related Adverse Events in Patients Treated with Immune Checkpoint Inhibitor Therapy, the severity of ICP inhibitor-induced colitis can be clinically classified into four grades based on the National Cancer Institute's CTCAE version 4 for diarrhea. Grade 1 features: <4 episodes of diarrhea per day above baseline and a mild increase in ostomy output compared to baseline. Grade 2 features: 4-6 episodes of diarrhea per day above baseline and a moderate increase in ostomy output compared to baseline. Grade 3 features: 7 or more episodes of diarrhea per day above baseline; incontinence; a significant increase in stool volume; a significant increase in ostomy output compared to baseline; and hospitalization is indicated. Grade 4 features: 8 or more episodes of diarrhea per day above baseline. Overall, symptoms are the same as grade 3, but are accompanied by life-threatening symptoms such as perforation, intestinal obstruction, and fever, and hospitalization is usually required. (Brahmer et al., "Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy": American Society of Clinical Oncology practice guideline. J Clin Oncol. 2018 Jun, 10;36(17):1714-1768.) Equivalent grading can be applied to patients with ICP inhibitor-induced colitis or enteritis.
[0010] Treatment of ICP inhibitor-induced colitis and enteritis is usually based on the severity of the symptoms and includes immunosuppression with systemically administered corticosteroids for moderate to severe symptoms and, in steroid-refractory cases, systemic administration of biologics such as infliximab.
[0011] The ASCO practice guideline recommends starting with an initial dose of 1 mg / kg / day prednisone or equivalent for grade 2 toxicity associated with corticosteroid administration in ICP inhibitor-induced colitis unless diarrhea is transient. Treatment with ICP inhibitors should be discontinued during corticosteroid treatment. If symptoms improve to grade 1 or worse, corticosteroids should be tapered over at least 4 to 6 weeks before resuming treatment with ICP inhibitors.
[0012] For grade 3 toxicity, the guidelines recommend administration of corticosteroids starting with an initial dose of 1–2 mg / kg / day prednisone or equivalent. If the patient recovers to grade 1 or worse, permanent discontinuation of CTLA-4 agents should be considered, while PD-1 and PD-L1 agents may be resumed. If symptoms persist for more than 3–5 days or recur after improvement, intravenous administration of corticosteroids or noncorticosteroid immunosuppressants (e.g., infliximab) should be considered.
[0013] For grade 4 toxicity, the guidelines recommend administering corticosteroids intravenously at 1–2 mg / kg / day (methyl)prednisolone or equivalent dose until symptoms improve to grade 1, then initiating a corticosteroid taper over 4–6 weeks. ICP inhibitors should be permanently discontinued. If symptoms are refractory within 2–3 days, administration of 5–10 mg / kg infliximab (e.g., 5 mg / kg infliximab every 2 weeks) should be considered. Guidance on the clinical management of ICP inhibitor toxicity is also provided in Hryniewicki et al., J Emerg Med. 2018 Oct;55(4):489-502.
[0014] Therefore, persistent class 2 ICP inhibitor-induced colitis and almost all class 3 / 4 ICP inhibitor-induced colitis usually require management with systemic corticosteroids. The use of prophylactic steroids (e.g., oral budesonide) has not been shown to be effective in treating episodes of diarrhea or colitis caused by ICP inhibitors. In patients resistant to treatment with systemic corticosteroids, systemic treatment with noncorticosteroids such as the anti-TNFα specific antibody infliximab is recommended. According to the ASCO practice guideline, enteritis, and thus general enteritis, can be treated with corticosteroids and / or infliximab, as can colitis.
[0015] Corticosteroids have several side effects, especially with prolonged use and / or high doses. In particular, patients treated with corticosteroids often become more susceptible to infections. Furthermore, the use of systemic corticosteroids results in higher infection rates as well as other potential side effects, including osteoporosis, fractures, osteonecrosis, increased cardiovascular risk, gastritis, peptic ulcer disease, worsening of diabetes, nervousness or restlessness, high blood pressure, insomnia, water retention and swelling, cataracts or glaucoma, muscle weakness, sudden mood swings, easy bruising, and weight gain. Therefore, long-term systemic treatment with corticosteroids should be avoided.
[0016] Furthermore, systemic treatment with high doses (e.g., 1-2 mg / kg / day prednisone or equivalent) of corticosteroids requires interruption (or permanent cessation) of treatment with ICP inhibitors. Such interruption impairs the anticancer efficacy of these ICP inhibitors. It is therefore desirable to avoid such interruptions.
[0017] Nonsteroidal agents with immunosuppressive effects, such as anti-TNFα antibodies, do not share many of the deleterious side effects of systemic treatment with corticosteroids, even though anti-TNFα antibodies such as infliximab are also usually administered systemically. Furthermore, infection rates have been reported to be numerically higher among patients with ICP inhibitor-induced colitis who received systemic corticosteroids for extended periods compared to administration of systemic anti-TNFα antibodies. Thus, early nonsteroidal immunosuppressive therapy may ensure a more favorable overall outcome (Wang et al., J Immuno Ther Cancer (2018) 6:37).
[0018] Currently, the standard of care for the treatment of severe ICP inhibitor-induced colitis or enteritis with anti-TNFα specific antibodies involves regular systemic administration of anti-TNFα antibodies by intravenous infusion. However, systemic administration of anti-TNFα antibodies in cancer patients also requires interruption of ICP inhibitor treatment, thereby compromising the success of cancer treatment with ICP inhibitors.
[0019] Furthermore, intravenous administration can lead to complications such as acute infusion reactions, hypersensitivity, and anaphylactic shock. Systemic administration of anti-TNFα antibodies also carries numerous risks associated with the systemic inhibition of the immune defense function of TNFα in patients, including, for example, infectious complications. Furthermore, immunogenicity to systemically administered antibodies can lead to their neutralization and secondary loss of response. Finally, melanoma and Merkel cell carcinoma have been reported in patients treated with TNF inhibitor therapy, including infliximab.
[0020] Thus, currently, treatment of ICP inhibitor-induced adverse events in the gastrointestinal tract, such as ICP inhibitor-induced colitis, enteritis and / or diarrhea, with moderate to severe symptoms, requires interruption of ICP inhibitor treatment and systemic administration of immunosuppressants, usually steroidal, which is detrimental to the efficacy of cancer treatment, causes undesirable side effects at the systemic level and, in the case of melanoma, leads to recurrence of the underlying disease.
[0021] There is a need for alternative treatments for gastrointestinal adverse events induced by ICP inhibitors, such as ICP inhibitor-induced diarrhea, colitis or enteritis, that can specifically target the inflamed tissues of the gastrointestinal tract, especially the ileum and colon, without the need to interrupt ICP inhibitor treatment.The treatment should in particular allow effective targeting of the tissues affected by inhibitor-induced adverse events in the gastrointestinal tract without the need for systemic administration.In addition, there is also a need for prophylactic treatments to prevent or delay the side effects that affect the gastrointestinal tract caused by ICP inhibitor treatment, especially for early treatment to prevent serious complications such as intestinal obstruction and perforation, as well as the need for urgent endoscopy, hospitalization and surgery. Summary of the Invention
[0022] Surprisingly, the inventors have found that treating immune-related adverse events induced by ICP inhibitors locally in the gastrointestinal tract thereby eliminates the need for systemic immunosuppressive treatment, overcoming the need to stop treatment with ICP inhibitors by allowing combined local treatment in the gastrointestinal tract with an immunosuppressive TNFα-specific antibody or functional fragment thereof and systemic treatment with an ICP inhibitor, thereby avoiding the compromise of successful cancer treatment with ICP inhibitors. Despite the fact that ICP inhibitors have been known for more than 15 years to treat cancer, it has not been suggested that TNFα-specific antibodies can be administered locally to treat or prevent immune-related side effects of ICP inhibitor therapy.
[0023] The present invention provides compositions for use in the localized treatment of the ileum and / or large intestine of ICP inhibitor-induced diarrhea, colitis or enteritis. Additionally, the present invention provides compositions for use in the localized treatment of the ileum and / or large intestine as a prophylactic treatment of ICP inhibitor-induced diarrhea, colitis or enteritis. In particular, the present invention provides compositions for use in the early treatment of ICP inhibitor-induced diarrhea to prevent more serious adverse events affecting the gastrointestinal tract, such as colitis or enteritis.
[0024] Accordingly, the present invention relates to the subject matter defined in the following items [1] to
[69] : [1] A pharmaceutical composition comprising an active agent selected from the group consisting of antibodies, functional fragments and derivatives thereof specific for tumor necrosis factor alpha (TNFα), for use in the treatment or prevention of at least one adverse event in the gastrointestinal tract induced by a cancer treatment in a patient, preferably induced by one or more immune checkpoint (ICP) inhibitors, wherein said treatment or prevention comprises local administration of said composition to an affected area of the gastrointestinal tract of said patient, for example the ileum and / or large intestine of said patient; or A pharmaceutical composition comprising an active agent selected from the group consisting of antibodies, functional fragments and derivatives thereof specific for tumor necrosis factor alpha (TNFα), for use in the treatment or prevention of at least one adverse event in the gastrointestinal tract induced by cancer therapy in a patient, preferably induced by one or more immune checkpoint (ICP) inhibitors, wherein said treatment or prevention comprises oral administration of said composition to said patient. [2] A pharmaceutical composition comprising an active agent selected from the group consisting of antibodies, functional fragments and derivatives thereof specific for tumor necrosis factor alpha (TNFα), for use in preventing the progression or worsening of at least one adverse event in the gastrointestinal tract induced by a cancer treatment in a patient, preferably induced by one or more immune checkpoint (ICP) inhibitors, wherein said prevention comprises local administration of said composition to an affected area of the gastrointestinal tract of said patient, for example the ileum and / or large intestine of said patient; or A pharmaceutical composition comprising an active agent selected from the group consisting of antibodies, functional fragments and derivatives thereof specific for tumor necrosis factor alpha (TNFα), for use in preventing the progression or worsening of at least one adverse event in the gastrointestinal tract induced by cancer treatment in a patient, preferably induced by one or more immune checkpoint (ICP) inhibitors, wherein said prevention comprises oral administration of said composition to said patient. [3] A composition for use according to [1] or [2], which allows for uninterrupted treatment, preferably systemic treatment, with one or more ICP inhibitors. [4] The composition for use according to any one of items [1] to [3], wherein the patient is receiving treatment, preferably systemic treatment, with one or more ICP inhibitors. [5] A composition for use according to item [4], wherein treatment with the one or more ICP inhibitors is interrupted for less than 4 weeks, preferably less than 2 weeks, more preferably less than 1 week, even more preferably less than 5, 4, 3, 2, or 1 days, and most preferably the treatment is not interrupted. [6] The composition for use according to any one of the preceding claims, wherein the patient is suffering from or at risk of developing ICP inhibitor-induced colitis. [7] The composition for use according to [6], wherein the ICP inhibitor-induced colitis is characterized by first-grade toxicity, and optionally, the treatment or prevention prevents progression to higher grade toxicity. [8] The composition for use according to [6], wherein the ICP inhibitor-induced colitis is characterized by second-grade toxicity, and optionally, the treatment or prevention prevents progression to higher grade toxicity. [9] The composition for use according to item [6], wherein the ICP inhibitor-induced colitis is characterized by grade 3 toxicity, and optionally, the treatment or prevention prevents progression to higher grade toxicity.
[10] The composition for use according to [6], wherein the ICP inhibitor-induced colitis is characterized by class 4 toxicity.
[11] The composition for use according to any one of items [7] to
[10] , wherein the treatment or prevention prevents cessation of treatment with one or more ICP inhibitors.
[12] The composition for use according to any one of the preceding claims, wherein the patient is suffering from or at risk of developing ICP inhibitor-induced enterocolitis.
[13] The composition for use according to item
[12] , wherein the ICP inhibitor-induced enteritis is characterized by first-grade toxicity, and optionally, the treatment or prevention prevents progression to higher-grade toxicity.
[14] The composition for use according to item
[12] , wherein the ICP inhibitor-induced enteritis is characterized by second-grade toxicity, and optionally, the treatment or prevention prevents progression to higher grade toxicity.
[15] The composition for use according to item
[12] , wherein the ICP inhibitor-induced enteritis is characterized by grade 3 toxicity, and optionally, the treatment or prevention prevents progression to higher grade toxicity.
[16] The composition for use according to item
[12] , wherein the ICP inhibitor-induced enteritis is characterized by class 4 toxicity.
[17] The composition for use according to any one of items
[13] to
[16] , wherein the treatment or prevention prevents cessation of treatment with one or more ICP inhibitors.
[18] The composition for use according to any one of the preceding claims, wherein the patient is suffering from or at risk of developing ICP inhibitor-induced diarrhea.
[19] The composition for use according to item
[18] , wherein the ICP inhibitor-induced diarrhea is characterized by first-grade toxicity, and optionally, the treatment or prevention prevents progression to higher grade toxicity.
[20] The composition for use according to
[18] , wherein the ICP inhibitor-induced diarrhea is characterized by second-grade toxicity, and optionally, the treatment or prevention prevents progression to higher grade toxicity.
[21] The composition for use according to item
[18] , wherein the ICP inhibitor-induced diarrhea is characterized by grade 3 toxicity, and optionally, the treatment or prevention prevents progression to higher grade toxicity.
[22] The composition for use according to item
[18] , wherein the ICP inhibitor-induced diarrhea is characterized by grade 4 toxicity.
[23] The composition for use according to any one of items
[19] to
[22] , wherein the treatment or prevention prevents cessation of treatment with one or more ICP inhibitors.
[24] A composition for use according to any of the preceding, wherein the composition is for use as a first line treatment in a patient with ICP inhibitor induced diarrhea, colitis or enteritis, and / or the patient has not been treated with a corticosteroid, and / or the patient is corticosteroid naive.
[25] A composition for use according to any of the preceding claims, wherein the composition is for use as a second line treatment in patients with steroid-refractory ICP inhibitor-induced diarrhea, colitis or enteritis.
[26] A pharmaceutical composition comprising an active agent selected from the group consisting of antibodies, functional fragments, and derivatives thereof specific for TNFα, for use in localized treatment of the ileum and / or large intestine of a patient as a prophylactic treatment of ICP inhibitor-induced diarrhea, colitis or enteritis.
[27] A composition for use according to item
[26] , wherein the local treatment prevents progression of an ICP inhibitor-induced adverse event in a patient, preferably grade 3 toxicity, preferably grade 2 toxicity, more preferably grade 1 toxicity, most preferably any symptomatic toxicity associated with ICP inhibitor-induced diarrhea, colitis or enteritis in the ileum and / or colon of the patient.
[28] A composition for use according to item
[27] , allowing simultaneous treatment with one or more ICP inhibitors, preferably systemic treatment.
[29] A composition for use according to any one of
[26] to
[28] , wherein the patient is simultaneously receiving systemic treatment with one or more ICP inhibitors.
[30] A composition for use according to any one of claims
[26] to
[29] , wherein use of the composition prevents or minimizes and / or slows down symptoms associated with ICP inhibitor-induced diarrhea, colitis or enteritis.
[31] The composition for use according to any of the preceding claims, wherein the ICP inhibitor is capable of targeting an immune checkpoint selected from the group consisting of the CTLA-4, PD-1, PD-L1, PDL2, B7-H3, B7-H4, BTLA, HVEM, TIM3, GAL9, LAG3, CSF-1R, VISTA, KIR, 2B4, CD160, CGEN-15049, CHK1, CHK2, A2aR, ADAR1, CD47, ICOS, TIGIT, and B-7 family of ligands.
[32] The composition for use according to any of the preceding claims, wherein the one or more ICP inhibitors are selected from the group consisting of an antibody specific for cytotoxic T-lymphocyte-associated protein-4 (CTLA-4), an antibody specific for programmed cell death protein-1 (PD-1), and an antibody specific for programmed death ligand 1 (PD-L1).
[33] The composition for use according to item
[32] , wherein the PD-1 specific antibody is selected from the group consisting of pembrolizumab, nivolumab, cemiplimab, and tislelizumab, the PD-L1 specific antibody is selected from the group consisting of atezolizumab, avelumab, and durvalumab, and the CTLA-4 specific antibody is selected from the group consisting of ipilimumab and tremelimumab.
[34] A composition for use according to
[32] or
[33] , wherein the one or more ICP inhibitors are a combination of an antibody specific for PD-1 and / or PD-L1 and an antibody specific for CTLA-4, preferably a combination of an antibody specific for PD-1 or PD-L1 and an antibody specific for CTLA-4.
[35] The composition for use according to any one of the preceding claims, wherein the one or more ICP inhibitors modulate the immune response in the patient.
[36] The composition for use according to any one of the preceding claims, wherein said one or more ICP inhibitors inhibit the proliferation of tumor cells in said patient.
[37] A composition for use according to any one of the preceding claims, wherein the patient is suffering from an infectious disease.
[38] The composition for use according to any one of the preceding claims, wherein the patient is a cancer patient.
[39] The composition for use according to item
[38] , wherein the cancer is selected from the group consisting of melanoma, lymphoma such as classical Hodgkin's lymphoma, glioma, urothelial carcinoma, Merkel cell carcinoma, renal carcinoma, head and neck squamous cell carcinoma, prostate cancer, breast cancer, colon cancer, and lung cancer.
[40] The cancer is selected from the group consisting of bone cancer, pancreatic cancer, skin cancer, head and neck cancer, cutaneous or intraocular malignant melanoma, uterine cancer, ovarian cancer, rectal cancer, cancer of the anal region, stomach cancer, testicular cancer, uterine cancer, carcinoma of the fallopian tubes, carcinoma of the endometrium, cervical cancer, vaginal cancer, vulvar cancer, Hodgkin's disease, non-Hodgkin's lymphoma, esophageal cancer, small intestine cancer, cancer of the endocrine system, cancer of the thyroid gland, cancer of the parathyroid gland, cancer of the adrenal gland, soft tissue sarcoma, cancer of the urethra, cancer of the penis, chronic or acute leukemia, acute myeloid leukemia, chronic myeloid leukemia, acute lymphoblastic leukemia, acute ... 39. The composition for use according to claim 38, wherein the cancer is selected from the group consisting of cancers of the genital tract, chronic lymphocytic leukemia, childhood solid tumors, lymphocytic lymphoma, bladder cancer, cancer of the kidney or ureter, cancer of the renal pelvis, neoplasms of the central nervous system (CNS), primary CNS lymphoma, tumor angiogenesis, spinal axis tumor, brain stem glioma, pituitary adenoma, Kaposi's sarcoma, epidermoid carcinoma, squamous cell carcinoma, T-cell lymphoma, environmentally induced cancers including those induced by asbestos, and combinations of said cancers.
[41] A composition for use according to any of the preceding claims, wherein the composition provides a therapeutically effective amount of a TNFα-specific antibody, or a functional fragment or derivative thereof, to the lumen of the ileum or large intestine of a patient to prevent, minimize, delay, or alleviate symptoms associated with ICP inhibitor-induced diarrhea, colitis, or enteritis.
[42] The composition for use according to any of the preceding claims, wherein the functional antibody fragment or derivative specific for TNFα is a Fab fragment, F(ab')2 fragment, Fab' fragment, scFv, dsFv, bispecific antibody, triabody, tetrabody, Fc fusion protein, camelid antibody, VHH, bolabody, VNAR, or minibody.
[43] The TNFα-specific antibody, its functional fragment, and derivative are disclosed in claim 2 of WO 2017 / 158092, claim 2 of WO 2017 / 158097, and claim 2 of WO from anti-TNFα antibodies and functional fragments and derivatives thereof having a light chain variable domain and / or a heavy chain variable domain comprising a complementarity determining region (CDR) having the amino acid sequence disclosed in claim 2 of WO2017 / 158079 and / or claim 2 of WO2017 / 158084, and from anti-TNFα antibodies and functional fragments and derivatives thereof comprising a heavy chain variable domain amino acid sequence and / or a light chain variable domain amino acid sequence according to claim 4 of the originally filed WO2017 / 158079, claims 5 and 6 of WO2017 / 158097, claims 5 and 6 of WO2017 / 158092, and claim 4 of WO2017 / 158084, the composition for use according to any of the preceding claims selected from the group consisting of infliximab, adalimumab, etanercept, certolizumab pegol, golimumab, and functional fragments and derivatives thereof, and combinations thereof.
[44] The composition for use according to
[43] , wherein the anti-TNFα antibody is infliximab, adalimumab, etanercept, certolizumab pegol, or golimumab.
[45] The composition for use according to
[43] , wherein the anti-TNFα antibody is infliximab.
[46] The composition for use according to
[43] , wherein the anti-TNFα antibody is adalimumab.
[47] The composition for use according to any one of items [1] to
[43] , wherein the functional fragment or derivative is a functional fragment or derivative of infliximab, adalimumab, etanercept, certolizumab pegol, or golimumab.
[48] The amino acid sequence of the TNFα-specific antibody, or a functional fragment or derivative thereof, is (i) a deletion at amino acid position 233P, 234V, 235A, and amino acid position 236; and amino acid 434A or amino acids 252Y, 254T, and 256E; and optionally also amino acids 239D, 330L, and 332E, or amino acids 326A, 332E, and 333A; and / or (ii) amino acids 380A and 434A, and optionally amino acid 307T; and / or (iii) amino acid 434W, and optionally amino acid 428E and / or amino acid 311R. (wherein the amino acid numbering refers to EU numbering.) 2. A composition for use according to any of the preceding claims, comprising
[49] The active agent comprises a CDR1 region having the amino acid sequence shown in SEQ ID NO: 3, a CDR2 region having the amino acid sequence shown in SEQ ID NO: 4, and a CDR3 region having the amino acid sequence shown in SEQ ID NO: 5. L A V domain, comprising a CDR1 region having the amino acid sequence shown in SEQ ID NO: 6, a CDR2 region having the amino acid sequence shown in SEQ ID NO: 7, and a CDR3 region having the amino acid sequence shown in SEQ ID NO: 8. H The composition for use according to any one of claims [1] to
[43] and
[48] , wherein the antibody comprises a domain.
[50] The active agent has the amino acid sequence shown in SEQ ID NO: 10. L domain, and V having the amino acid sequence shown in SEQ ID NO:9 H The composition for use according to any one of claims [1] to
[43] and
[48] , wherein the antibody comprises a domain.
[51] The composition for use according to any one of items [1] to
[43] ,
[49] and
[50] , wherein the active agent is an antibody comprising an Fc region comprising amino acids 236 to 451 of the amino acid sequence shown in SEQ ID NO:11.
[52] The composition for use according to any of items [1] to
[43] , wherein the active agent is an antibody comprising a light chain having the amino acid sequence shown in SEQ ID NO: 1, and a heavy chain having the amino acid sequence shown in SEQ ID NO: 11, 14, 15 or 16.
[53] A composition for use according to any one of the preceding claims, wherein the treatment comprises oral administration of the composition.
[54] A composition for use according to item
[53] , wherein the composition is a solid dosage form in the form of pellets, granules, microparticles, nanoparticles, minitablets, spheres, capsules, tablets, or a multiparticulate drug delivery system coated with a delayed release coating that prevents release of the active agent before entering the ileum, terminal ileum or ileocolonic region of the gastrointestinal (GI) tract.
[55] The composition for use according to
[54] , wherein the delayed release coating comprises at least one component selected from a coating material that degrades due to pH, a coating material that degrades due to time, a coating material that degrades due to an enzymatic trigger in the intestinal environment, and combinations thereof.
[56] The pH-disintegrable coating material is selected from the group consisting of polyvinyl acetate phthalate; trimellitate cellulose acetate; hydroxypropyl methylcellulose phthalate HP-50, HP-55 or HP-55S; cellulose acetate phthalate; hydroxypropyl methylcellulose acetate succinate (HPMCAS); poly(methacrylic acid, ethyl acrylate) 1:1 (Eudragit® L100-55, Eudragit® L30D-55); poly(methacrylic acid, methyl methacrylate) 1:1 (Eudragit® L-100, Eudragit® L12.5); poly(methacrylic acid, methyl methacrylate) 1:2 (Eudragit® S-100, Eudragit® S12.5, Eudragit® FS30D), and combinations thereof; the time-degradable coating material is selected from poly(ethyl acrylate, methyl methacrylate) 2:1 (e.g. Eudragit® NM 30D, Eudragit® NE 30D); poly(ethyl acrylate, methyl methacrylate, methacrylic acid) 7:3:1 (e.g. Eudragit® RS 30D); ethyl cellulose (e.g. Surelease® or Aquacoat ECD); poly(ethyl acrylate, methyl methacrylate, trimethylammonioethyl methacrylate chloride) 1:2:0.2 (e.g. Eudragit® RL 30D); polyvinyl acetate (e.g. Kollicoat® SR 30D); and combinations thereof; and A composition for use according to
[53] or
[54] , wherein the coating material that degrades by an enzymatic trigger in the intestinal environment is selected from the group consisting of hemicellulose, chondroitin sulfate; cyclodextrin; pectin; guar gum; chitosan; inulin; lactulose; raffinose; stachyose; alginate; dextran; xanthan gum; locust bean gum; arabinogalactan; amylose; pullulan; carrageenan; scleroglucan; chitin; curdlan; levan; amylopectin; starch; resistant starch; azo compounds degraded by azo bond-degrading bacteria; and combinations thereof.
[57] The composition according to any one of
[54] to
[56] , wherein the delayed release coating comprises a combination of at least one coating material that is degraded by pH and at least one coating material that is degraded by an enzymatic trigger in the intestinal environment.
[58] The delayed release coating is selected from the group consisting of hemicellulose, polyvinyl acetate phthalate, cellulose acetate trimellitate, hydroxypropyl methylcellulose phthalate HP-50, HP-55, or HP-55S, cellulose acetate phthalate, hydroxypropyl methylcellulose acetate succinate (HPMCAS), poly(methacrylic acid, ethyl acrylate) 1:1, poly(methacrylic acid, methyl methacrylate) 1:1, poly(methacrylic acid, methyl methacrylate) 1:2, chondroitin sulfate, pectin, The composition according to any one of items
[54] to
[56] , comprising at least one component selected from the group consisting of cellulose acetate, guar gum, chitosan, inulin, lactulose, raffinose, stachyose, alginate, dextran, xanthan gum, locust bean gum, arabinogalactan, amylose, cyclodextrin, pullulan, carrageenan, scleroglucan, chitin, curduran, levan, amylopectin, starch, resistant starch, azo compounds decomposed by azo bond-decomposing bacteria, and combinations thereof.
[59] The composition according to any one of items
[53] to
[58] , wherein upon oral administration of the composition, release of the antibody or functional fragment thereof begins in the ileum, terminal ileum, ileocolonic region, ascending colon, transverse colon, or descending colon.
[60] The composition according to any of items
[54] to
[59] , wherein the delayed release coating comprises at least one pH-sensitive (enteric) polymer, preferably poly(methacrylic acid, methyl methacrylate) 1:2 (e.g. Eudragit® S or L), in combination with at least one polysaccharide selected from hemicellulose, chondroitin sulfate, cyclodextrin, chitosan, dextran, arabinogalactan, amylose, pullulan, carrageenan, scleroglucan, chitin, curdlan, levan, amylopectin, starch, resistant starch, azo compounds degraded by azo-bond-degrading bacteria, and combinations thereof, preferably resistant starch.
[61] The composition according to any one of items
[54] to
[59] , wherein the delayed release coating comprises, as the only polymer, one or more pH-sensitive polymers, e.g., Eudragit® S and / or L; or wherein the delayed release coating consists essentially of at least one pH-sensitive polymer, e.g., Eudragit® S and / or L.
[62] A composition for use according to any one of items [1] to
[52] , wherein the treatment comprises rectal administration of the composition and / or the composition is an enema liquid, gel, foam, or suppository.
[63] A composition for use according to any of the preceding claims, comprising at least one additive selected from a hydrophilic polymer, a filler, a hydrophilic binder, a disintegrant, an anti-adherent, a surfactant, a stabilizer, a protease resistance enhancing agent, a plasticizer, a coalescing agent, a lubricant, a buffering agent, and / or an acidifying agent.
[64] A composition for use according to any of the preceding claims, wherein the active agent is an electronic drug capsule designed to deliver the active agent directly to the ileum and / or colon, or is provided by genetically modified bacteria expressing a TNFα binding protein.
[65] A composition for use according to any one of the preceding claims, wherein said local treatment results in retention of the antibody or functional fragment thereof in the gastrointestinal wall and not primarily systemic release to the remainder of the body.
[66] A composition for use according to any of the preceding claims, wherein the treatment comprises administering to the patient the antibody or functional fragment thereof once a week, twice a week, once every three days, once every two days, once a day, twice a day, or three times a day.
[67] A composition for use according to any of the preceding claims in the local treatment of the ileum, terminal ileum, cecum, ascending colon, transverse colon, and / or descending colon of said patient.
[68] A composition for use according to any of the preceding, wherein the topical treatment of ICP inhibitor-induced diarrhea, colitis or enteritis is indicated by one or more symptoms selected from the group consisting of diarrhea with fewer than 4 stools above baseline, diarrhea with 4-6 stools above baseline, diarrhea with 7 or more stools above baseline, diarrhea with 8 or more stools above baseline, abdominal pain, nausea, cramps, bloody or mucus in the stool, or change in bowel habits, fever, abdominal bloating, constipation and constipation.
[69] A composition for use according to any of the preceding, wherein said topical treatment prevents, minimizes and / or slows, or alleviates one or more symptoms associated with ICP inhibitor-induced diarrhea, colitis, or enteritis selected from the group consisting of diarrhea with fewer than 4 stools above baseline, diarrhea with 4-6 stools above baseline, diarrhea with 7 or more stools above baseline, diarrhea with 8 or more stools above baseline, abdominal pain, nausea, cramps, bloody or mucus in the stool, or altered bowel habits, fever, abdominal bloating, constipation, and constipation. [Brief description of the drawings]
[0025] [Figure 1] Shown is the percentage change in body weight compared to day 0 (see Example 3). Data are expressed as mean ± SE. n = 5-12 per group.
[0026] [Diagram 2] Histological and endoscopic scores over time for treated animals are shown (see Example 3). *: p<0.05 as determined by one-way ANOVA with Dunnett's multiple comparison post-hoc test used to compare all groups to the vehicle control group. Data are presented as mean ± SE. n=5-12 per group.
[0027] [Diagram 3]Histological scores on the day of sacrifice (day 49) are shown (see Example 3). **: p<0.01, ***: p<0.005 as determined by one-way ANOVA with Dunnett's multiple comparison post-hoc test used to compare all groups to the vehicle control group. Data are expressed as mean ± SE. n=5-12 per group.
[0028] [Figure 4] Cytokine concentrations in the colon of treated mice measured on day 49 (see Example 3) are shown. *: p<0.05 as determined by one-way ANOVA with Dunnett's multiple comparison post-hoc test used to compare all groups to the vehicle control group. Data are presented as mean ± SE. n=5-12 per group.
[0029] [Diagram 5] Figure 1 shows the effect on histological scores after cV1q-huFc treatment (see Example 4). Total histological score, which is the sum of the individual scores (0-5 each) for inflammation, crypt damage, erosion, hyperplasia, and edema in the proximal, middle, and distal colon on day 42. *: p<0.05, **: p<0.01, ****: p<0.0001 as measured by Kruskal-Wallis with Dunnett's multiple comparison post-hoc test used to compare all groups with their respective vehicle control groups. Data are expressed as mean ± SE. n=6-12 per group. Intraperitoneal administration of cV1q was used as a control.
[0030] [Figure 6] Effects on cytokines in the colon are shown (see Example 4). Cytokines in colon tissue were measured by ELISA and results were normalized to mg tissue weight. *: p<0.05, **: p<0.01, ***: p<0.005, ****: p<0.001 as measured by one-way ANOVA with Dunnett's multiple comparison post-hoc test used to compare all groups to the vehicle control group. Data are expressed as mean ± SE. n=6-12 per group. Intraperitoneal administration of cV1q was used as a control.
[0031] [Figure 7] Figure 1 shows the mean plasma drug concentrations of cV1q-huFc in healthy and colitic Tg32-SCID mice after rectal administration (see Example 5). Plasma samples were collected at 1, 2, 4, 8, 24, and 48 hours for single-dose (SD) animals and at 24, 48, 72, 96, 120, and 144 hours after the first dose for multiple-dose (MD) animals. Plasma concentrations of cV1q-huFc were measured by Imperacer® Immuno-PCR. SD and MD profiles are based on two subgroups (SD: 1, 4, and 24 hours from subgroup 1, 2, 8, and 48 hours from subgroup 2; MD: 24, 72, and 120 hours from subgroup 1, 48, 96, and 144 hours from subgroup 2) due to blood collection limitations. Data are presented as mean ± SD (n=5-7).
[0032] [Figure 8] Median cV1q-huFc plasma concentrations in healthy and colitic mice after intracecal dosing are shown (see Example 6). Plasma samples were taken at sacrifice, 1, 4, 8, 12 and 24 hours after a single dose in Tg32-SCID mice and 120 hours after the first dose in repeatedly dosed animals. Plasma concentrations of cV1q-huFc were measured by Imperacer® Immuno-PCR. Data are presented as median ± IQR (n=4). IC: intracecal; IR: intrarectal.
[0033] [Figure 9]Median cV1q-huFc concentrations in the proximal and distal colon after intracecal or rectal administration are shown (see Example 6). At sacrifice, proximal and distal colon tissue samples were taken 1, 4, 8, 12, and 24 hours after a single dose in Tg32-SCID mice, and 120 hours after the first dose in repeatedly dosed animals. Tissue samples were rinsed, weighed, and homogenized in 0.3 mL PBS. cV1q-huFc concentrations in the supernatants were measured by a commercial IgG ELISA. The resulting concentrations (pg / mL) were then normalized to tissue weight. Data are presented as median ± IQR (n=4). IC: intracecal; IR: intrarectal. *: Median values for BLQ in the proximal colon at 1 and 4 hours in healthy animals, at 1, 4, and 8 hours in colitic mice treated with 300 μg cV1q-huFc, and at 12 hours in the distal colon in colitic mice treated with 100 μg cV1q-huFc.
[0034] [Figure 10] The effect of Ab-REW and infliximab on IFNγ production after nivolumab treatment is shown (see Example 7). CD14+ monocytes were isolated from PBMCs and differentiated into monocyte-derived dendritic cells (mo-DCs) for 7 days by adding GM-CSF and IL-4 to the cell culture medium. CD4+ T cells were also isolated from PBMCs. CD4+ T cells and mo-DCs were combined at a T cell to DC ratio of 5:1 and incubated with nivolumab (10 μg / mL) and serially diluted Ab-REW or infliximab (50-0.003 μg / mL) for 5 days. The concentration of IFNγ in the cell culture supernatant was then measured by ELISA. Data are presented as mean (±SE) of n=3. Where possible, 4-PL nonlinear regression was performed. The lower dotted line represents the mean secretion of IFNγ from untreated cells. The upper dotted line represents the mean secretion of IFNγ in the presence of nivolumab alone (n=6 for all controls). Detailed Description of the Invention
[0035] The present invention is described below with respect to antibodies specific for tumor necrosis factor alpha (TNFα), and functional fragments and derivatives thereof, which represent the most preferred embodiments. All embodiments described below apply equally mutatis mutandis to antibodies and functional fragments and derivatives thereof directed against other targets (antigens). Targets of these antibodies and functional fragments thereof include, but are not limited to, anti-inflammatory cytokines and their receptors, such as IL-13; pro-inflammatory cytokines and their receptors, such as CD20, IL-6, IL-12 and IL-23 (IL-12 / IL-23p40, IL-23p19), IL-17, IL-21; cell adhesion molecules, such as MadCAM-1, ICAM-1; CC chemokine receptors and their ligands, such as CCR5, CCR9; integrins, such as alpha4beta7, beta7, alpha2beta1, alphaEbeta7; Toll-like receptors, such as TLR2, TLR9; eotaxins, such as Eotaxin-1; members of the tumor necrosis factor receptor superfamily, such as OX40; matrix metalloproteinases, such as MMP-9; CXC motif chemokines, such as IP-10; and other proteins, such as CD20. Preferred targets are α4β7 integrin and IL-23.
[0036] According to a first aspect of the invention, the present invention relates to a pharmaceutical composition comprising an active agent selected from the group consisting of antibodies specific for tumor necrosis factor alpha (TNFα) and functional fragments and derivatives thereof, for use in the treatment or prevention of at least one adverse event in the gastrointestinal tract induced by cancer therapy in a patient, preferably induced by one or more immune checkpoint (ICP) inhibitors, wherein said treatment or prevention comprises local administration of said composition to the ileum and / or large intestine of said patient.
[0037] The present invention further relates to a pharmaceutical composition comprising an active agent selected from the group consisting of antibodies specific for tumor necrosis factor alpha (TNFα) and functional fragments and derivatives thereof, for use in localized treatment of the ileum and / or colon of patients suffering from immune checkpoint (ICP) inhibitor-induced colitis or enteritis or diarrhea. The composition of the present invention allows not to interrupt systemic treatment with one or more ICP inhibitors. This has the advantage that the success of cancer treatment with ICP inhibitors does not have to be compromised. Furthermore, localized treatment with antibodies specific for TNFα and functional fragments and derivatives thereof means that the use of corticosteroids and systemic administration of antibodies specific for TNFα and functional fragments and derivatives thereof is unnecessary, thereby minimizing the undesirable side effects of such treatment.
[0038] In the context of the present invention, the term "antibody" is used as a synonym for "immunoglobulin" (Ig), defined as a protein belonging to the classes IgG, IgM, IgE, IgA, or IgD (or any subclass thereof), and includes all previously known antibodies, functional fragments and derivatives thereof. In the context of the present invention, a "functional fragment or derivative" of an antibody / immunoglobulin is defined as an antigen-binding fragment or other derivative of a parent antibody that essentially maintains the antigen-binding properties of such parent antibody. In a preferred embodiment, the functional fragment or derivative of the antibody comprises at least a functional Fc portion exhibiting an effector function. In one embodiment, the antibody is capable of binding to human FcRn.
[0039] An "antigen-binding fragment or derivative" of an antibody / immunoglobulin is defined as a fragment (e.g., variable region of IgG) or derivative that retains the antigen-binding region. The "antigen-binding region" of an antibody is typically found in one or more hypervariable regions of the antibody, i.e., CDR-1, -2, and / or -3 regions. The "antigen-binding fragment" of the present invention includes F(ab')2 and Fab fragment domains. The "functional fragments and derivatives" of the present invention include Fab fragments, F(ab')2 fragments, Fab' fragments, scFv, dsFv, bispecific antibodies, triabodies, tetrabodies, Fc fusion proteins, borafides, camelid antibodies, VHH, VNAR, and minibodies. The F(ab')2 or Fab domain may be engineered to minimize or completely remove intermolecular disulfide interactions occurring between the CH1 and CL domains. The antibody or functional fragment of the present invention may be part of a bifunctional or multifunctional construct.
[0040] Functional fragments and derivatives of the present invention include, but are not limited to, Fab fragments, F(ab')2 fragments, Fab' fragments, scFvs, and bispecific antibodies.
[0041] Fab fragments can be obtained as purified digestion products after digestion of antibodies specific for TNFα with cysteine proteases such as papain (EC 3.4.22.2). F(ab')2 fragments can be obtained as purified digestion products after digestion of antibodies specific for TNFα with pepsin (EC 3.4.23.1) or IdeS (immunoglobulin degrading enzyme from Streptococcus pyogenes; EC 3.4.22). Fab' fragments can be obtained from F(ab')2 fragments under mild reducing conditions, whereby each F(ab')2 molecule generates two Fab' fragments.
[0042] scFv is a variable light ("V L ") domains and variable weight ("V H ") domains are linked by a peptide bridge.
[0043] A "bispecific antibody" is a dimer consisting of two fragments (hereinafter referred to as bispecific antibody-forming fragments) each having a variable region linked via a linker or the like. L and two V H Bispecific antibody-forming fragments include V L and V H , V L and V L , V H and V H etc., preferably V H and V L In the bispecific antibody-forming fragment, the linker binding to the variable region is not particularly limited, but is preferably short enough to avoid non-covalent binding between the variable regions in the same fragment. The length of such a linker can be appropriately measured by a person skilled in the art, but typically, 2 to 14 amino acids, preferably 3 to 9 amino acids, and particularly 4 to 6 amino acids are used. In this case, the V encoded by the same fragment is preferably 0.01 to 0.05. L and V H V on the same chain L and V H and are linked via a linker that is short enough to avoid non-covalent binding between the bispecific antibody-forming fragments and to avoid the formation of a single-chain variable region fragment that can form a dimer with another fragment. The dimer can be formed via either covalent or non-covalent bonds, or both, between the bispecific antibody-forming fragments.
[0044] Furthermore, bispecific antibody-forming fragments can be linked via a linker or the like to form a single-chain bispecific antibody (sc(Fv)2). By linking bispecific antibody-forming fragments using a long linker of about 15 to 20 amino acids, non-covalent bonds can be formed between the bispecific antibody-forming fragments present on the same chain to form a dimer. Based on the same principle as in the preparation of bispecific antibodies, polymerized antibodies such as trimers or tetramers can also be prepared by linking three or more bispecific antibody-forming fragments.
[0045] In one embodiment, the functional antibody fragment or derivative is a Fab fragment, F(ab')2 fragment, Fab' fragment, scFv, dsFv, bispecific antibody, triabody, tetrabody, Fc fusion protein, borahody, camelid antibody, VHH, VNAR, or minibody. Preferred functional fragments or derivatives for use in the present invention are Fab fragments, F(ab')2 fragments, Fab' fragments, scFv, and bispecific antibodies.
[0046] The antibody or functional fragment or derivative thereof contained in the composition of the present invention specifically binds to TNFα, but is otherwise not particularly limited. As used herein, the terms "anti-TNFα antibody", "TNFα antibody", "TNFα-specific antibody" and "antibody specific for TNFα" are interchangeable. In their most common form (and when no defined reference is mentioned), "specific" and "specific binding" refer to the ability of the antibody or functional fragment or derivative to distinguish between human TNFα and unrelated biomolecules, for example as determined according to specificity assay methods known in the art. Such methods include, but are not limited to, Western blots and enzyme-linked immunosorbent assay (ELISA) tests. For example, a standard ELISA assay can be performed. Typically, the measurement of binding specificity is performed using a set of about 3-5 unrelated biomolecules, such as milk powder, BSA, transferrin, etc., rather than a single reference biomolecule. In one embodiment, specific binding refers to the ability of the antibody or fragment to distinguish between human TNFα and human TNFβ. In a preferred embodiment of the present invention, the TNFα antibody or functional fragment thereof is a TNFα antibody. In an alternatively preferred embodiment of the invention, said TNFα antibody or functional fragment thereof is a functional fragment or derivative of a TNFα antibody.
[0047] In a preferred embodiment of the present invention, the antibody of the present invention is a non-fucosylated antibody or an antibody with reduced fucosylation. The term "antibody with reduced fucosylation" as used herein refers to an antibody in which less than 90% of the antibody's N-glycans are fucosylated. Methods for measuring the fucosylation rate are known in the art. In one embodiment, less than 75%, or less than 50%, or less than 25% of the antibody's N-glycans are fucosylated. Most preferably, less than 10% of the antibody's N-glycans are fucosylated. In a particular embodiment, the N-glycans of the antibody of the present invention do not contain any fucose. Preferably, less than 90% of the antibody's N-glycans at N297 (EU numbering) are fucosylated. In another embodiment, less than 75%, or less than 50%, or less than 25% of the antibody's N-glycans at N297 (EU numbering) are fucosylated. Most preferably, less than 10% of the N-glycans at N297 (EU numbering) of said antibody are fucosylated. In another embodiment, the N-glycan at N297 of said antibody does not contain fucose.
[0048] Nonfucosylated antibodies, also called afucosylated antibodies, can be generated in a variety of ways. For example, synergistic knockdown of the genes for α1,6-fucosyltransferase (FUT8) and GDP-mannose 4,6-dehydratase (GMD) in CHO cells can be used to generate monoclonal antibody variants that are fully afucosylated and have enhanced ADCC (see, for example, Imai, Nishitani et al. (2007) BMC Biotechnol. 7, 84). A method using zinc finger nucleases (ZFNs) to cleave the FUT8 gene in the region encoding the catalytic core of α1,6-fucosyltransferase, thus destroying the corresponding enzyme function in CHO cells, can be used to generate monoclonal antibodies that are completely devoid of core fucose (see, for example, Malphettes et al. (2010) Biotechnol. Bioeng. 106, 774-783).
[0049] Antibodies with reduced fucosylation can be prepared by adding a decoy substrate, such as 2-deoxy-2-fluoro-2-fucose, to the culture medium (see, e.g., Dekker et al., (2016) Sci Rep 6:36964), which reduces the incorporation of fucose into IgG-Fc glycans.
[0050] In another embodiment, the antibody of the present invention has a high sialic acid content. Increased cytidylation can be achieved, for example, by co-transfection of cytidine monophosphate-sialic acid synthase (CMP-SAS), cytidine monophosphate-sialic acid transporter (CMP-SAT), and α2,3-sialyltransferase (see, for example, Son et al. (2011) Glycobiology 21, 1019-1028).
[0051] Preferably, the antibodies of the present invention have high affinity for human FcRn at pH 6. High affinity binding of an antibody to human FcRn at pH 6 has a K of less than 500 nM. D Preferably, the binding affinity is characterized by a K value for high affinity binding at pH 6. D For example, the K value characterizing affinity at pH 6 is less than 400 nM, or less than 300 nM, or less than 200 nM. D Values may range from 1 to 500 nM, or 2 to 400 nM, or 3 to 300 nM, or 4 to 200 nM, or 5 to 100 nM.
[0052] In one embodiment, the affinity of the antibodies of the invention for human FcRn at pH 6 is greater than the affinity of infliximab for human FcRn at pH 6.0.
[0053] The affinity of the antibodies of the present invention for human FcRn is preferably measured by surface plasma resonance (SPR).
[0054] Several monoclonal antibodies against TNFα have been described in the prior art. Meager et al. (Hybridoma, 6, 305-311, 1987) describe mouse monoclonal antibodies against recombinant TNFα. Fendly et al. (Hybridoma, 6, 359-370, 1987) describe the use of mouse monoclonal antibodies against recombinant TNFα in defining neutralizing epitopes on TNF. Furthermore, International Patent Application WO 92 / 11383 discloses recombinant antibodies, including CDR-grafted antibodies, specific for TNFα. U.S. Patent No. 5,919,452 discloses anti-TNFα chimeric antibodies and their use in the treatment of pathologies associated with the presence of TNFα. Further anti-TNFα antibodies are disclosed in Stephens et al. (Immunology, 85, 668-674, 1995), GB-A-2 246 570, GB-A-2 297 145, US 8,673,310, US 2014 / 0193400, EP 2 390 267 B1, US 8,293,235, US 8,697,074, WO2009 / 155723 A2, and WO2006 / 131013 A2.
[0055] Currently approved anti-TNFα antibodies include: (i) infliximab (Remicade®, Inflectra®, Remsima®), a chimeric IgG monoclonal antibody; (ii) etanercept (Enbrel®), a TNFR2 dimeric fusion protein with IgG1 Fc; (iii) adalimumab (Humira®), a fully human monoclonal antibody (mAb); (iv) certolizumab pegol (Cimzia®), a PEGylated Fab fragment; and (v) golimumab (Simponi®), a human IgG1 monoclonal antibody. Reference herein to an antibody or functional fragment or derivative thereof INN includes biosimilars and biomodified versions thereof. In one embodiment of the invention, said anti-TNFα antibody or functional fragment or derivative thereof is selected from infliximab, adalimumab, etanercept, certolizumab pegol, and golimumab, or a functional fragment or derivative thereof. In another embodiment of the invention, said antibody or functional fragment or derivative thereof is selected from the anti-TNFα antibodies or functional fragments or derivatives thereof disclosed in WO2017 / 158092, WO2017 / 158097, WO 2017 / 158084, and WO2017 / 158079. In yet another embodiment of the invention, at least one of the antibodies or functional fragments or derivatives thereof is an anti-TNFα antibody or functional fragment or derivative thereof having a light chain variable domain and / or a heavy chain variable domain comprising complementarity determining regions (CDRs) having the amino acid sequences disclosed in PCT applications WO2017 / 158092, WO2017 / 158097, WO2017 / 158084, and WO2017 / 158079.
[0056] In a preferred embodiment of the present invention, the antibody or functional fragment or derivative thereof is selected from anti-TNFα antibodies having a light chain variable domain and / or a heavy chain variable domain including one or more CDRs having the amino acid sequences disclosed in SEQ ID NOs: 7, 9, 12, 14, 24, and 25 of WO2017 / 158079, SEQ ID NOs: 7 to 11 and 6 of WO2017 / 158097, SEQ ID NOs: 7 to 12 of WO2017 / 158092, and SEQ ID NOs: 1 to 4, 7, and 6 of WO2017 / 158084, or functional fragments or derivatives thereof, and combinations thereof. In another preferred embodiment of the present invention, the antibody or functional fragment or derivative thereof is selected from an anti-TNFα antibody or functional fragment or derivative thereof having a light chain variable domain and a heavy chain variable domain comprising CDRs having the amino acid sequences disclosed in claim 2 of originally filed WO2017 / 158079, claim 2 of WO2017 / 158097, claim 2 of WO2017 / 158092, and / or claim 2 of WO2017 / 158084. In yet another preferred embodiment of the present invention, the anti-TNFα antibody or functional fragment or derivative thereof is selected from the group consisting of anti-TNFα antibodies having a heavy chain variable domain amino acid sequence and / or a light chain variable domain amino acid sequence according to claim 4 of WO2017 / 158079, claims 5 and 6 of WO2017 / 158097, claims 5 and 6 of WO2017 / 158092, and claim 4 of WO2017 / 158084, or functional fragments or derivatives thereof, and combinations thereof.
[0057] In a preferred embodiment, the antibody comprises: (i) a CDR1 region having an amino acid sequence as set forth in SEQ ID NO:3, a CDR2 region having an amino acid sequence as set forth in SEQ ID NO:4, and a CDR3 region having an amino acid sequence as set forth in SEQ ID NO:5; L and (ii) a V domain comprising a CDR1 region having an amino acid sequence as set forth in SEQ ID NO:6, a CDR2 region having an amino acid sequence as set forth in SEQ ID NO:7, and a CDR3 region having an amino acid sequence as set forth in SEQ ID NO:8. HMore preferably, the antibody comprises a V domain having an amino acid sequence as set forth in SEQ ID NO:10. L domain, and a V having an amino acid sequence as shown in SEQ ID NO:9. H Includes the domain.
[0058] In another preferred embodiment (which may be combined with any one of the embodiments in the previous paragraph), the antibody comprises an Fc region comprising amino acids 236 to 451 of the amino acid sequence as set forth in SEQ ID NO:11.
[0059] Most preferably, the antibody comprises a light chain having the amino acid sequence as shown in SEQ ID NO:1, and a heavy chain having the amino acid sequence as shown in SEQ ID NO:11, 14, 15 or 16.
[0060] In one embodiment, the antibody comprises a light chain having the amino acid sequence as set forth in SEQ ID NO:1, and a heavy chain having the amino acid sequence as set forth in SEQ ID NO:11. In another embodiment, the antibody comprises a light chain having the amino acid sequence as set forth in SEQ ID NO:1, and a heavy chain having the amino acid sequence as set forth in SEQ ID NO:14. In another embodiment, the antibody comprises a light chain having the amino acid sequence as set forth in SEQ ID NO:1, and a heavy chain having the amino acid sequence as set forth in SEQ ID NO:15. In another embodiment, the antibody comprises a light chain having the amino acid sequence as set forth in SEQ ID NO:1, and a heavy chain having the amino acid sequence as set forth in SEQ ID NO:16.
[0061] In yet another embodiment, the antibody comprises a light chain consisting of the amino acid sequence as set forth in SEQ ID NO:1, and a heavy chain consisting of the amino acid sequence as set forth in SEQ ID NO:11. In yet another embodiment, the antibody comprises a light chain consisting of the amino acid sequence as set forth in SEQ ID NO:1, and a heavy chain consisting of the amino acid sequence as set forth in SEQ ID NO:14. In yet another embodiment, the antibody comprises a light chain consisting of the amino acid sequence as set forth in SEQ ID NO:1, and a heavy chain consisting of the amino acid sequence as set forth in SEQ ID NO:15. In yet another embodiment, the antibody comprises a light chain consisting of the amino acid sequence as set forth in SEQ ID NO:1, and a heavy chain consisting of the amino acid sequence as set forth in SEQ ID NO:16.
[0062] In further embodiments, the TNFα antibody is infliximab, adalimumab, etanercept, certolizumab pegol, or golimumab. In alternative further embodiments, the TNFα antibody functional fragment or derivative is a functional fragment or derivative of infliximab, adalimumab, etanercept, certolizumab pegol, or golimumab.
[0063] Said TNFα-specific antibodies or functional fragments or derivatives thereof may further comprise one or more modifications, such as in the form of added or substituted residues, that improve stability, specificity or targeting. They may include such modifications known in the art. In one embodiment of the invention, at least one said TNFα-specific antibody or functional fragment or derivative thereof comprises one or more of such modifications disclosed in US 8,871,204, US 6,737,056, US 8,742,074, WO2002 / 060919, WO2017 / 158426, International Patent Applications PCT / EP2018 / 074525 (WO2019 / 057567 A1), PCT / EP2018 / 074523 (WO2019 / 057565 A1), or PCT / EP2018 / 074522 (WO2019 / 057564 A1).
[0064] In a particular embodiment, the amino acid sequence of the antibody heavy chain comprises i) a deletion at amino acid positions 233P, 234V, 235A, and 236; amino acid 434A or amino acids 252Y, 254T, and 256E; optionally amino acids 239D, 330L, and 332E, or amino acids 326A, 332E, and 333A (EU numbering); and / or ii) amino acids 380A and 434A, and optionally amino acid 307T (EU numbering); and / or iii) amino acid 434W, and optionally amino acid 428E and / or amino acid 311R (EU numbering). In another particular embodiment, the amino acid sequence of the antibody heavy chain comprises a mutation at one or more positions selected from the group consisting of 311, 428, 434, 435, and 438 (EU numbering). Preferably, the amino acid sequence of the antibody heavy chain comprises amino acids 434W, 428E, and 311R (EU numbering). Most preferably, the antibody comprises an Fc domain comprising amino acids 236 to 451 of the amino acid sequence as set forth in SEQ ID NO: 11. Antibodies having specific amino acids described in this paragraph can be obtained by introducing substitutions into the heavy chain sequence, for example the sequence set forth in SEQ ID NO: 2.
[0065] Unless otherwise specified herein, references to residue numbers in the amino acid sequence of an antibody correspond to residue numbering according to the EU numbering system, also known as the EU index, as described in Kabat et al., "Sequences of Proteins of Immunological Interest" (5th ed. Public Health Service, National Institutes of Health, Bethesda, Md., 1991. See, e.g., WO2006 / 073941).
[0066] The pharmaceutical composition of the invention may comprise as active agent one antibody specific for TNFα or a functional fragment or derivative thereof, or several different antibodies specific for TNFα and / or for functional fragments or derivatives of antibodies specific for TNFα. For example, the composition of the invention may comprise 1, 2, 3, 4 or 5 different antibodies specific for TNFα and for functional fragments or derivatives of antibodies specific for TNFα.
[0067] As used herein, the terms "treat", "treating" and "treatment" with respect to ICP inhibitor induced diarrhea, colitis or enteritis refer to the administration of a TNFα specific antibody or functional fragment or derivative thereof as part of a composition of the invention to prevent, minimize or delay the onset of symptoms, complications or similar biochemical signs of ICP inhibitor induced diarrhea colitis or enteritis or to alleviate or minimize symptoms, complications or similar biochemical signs of ICP inhibitor induced diarrhea colitis or enteritis.
[0068] The term "local treatment" in the context of the present invention is used to describe the local administration of a TNFα antibody-containing composition, as opposed to the systemic administration of said composition, e.g. by intravenous infusion or subcutaneous injection, used in commercial products. However, local treatment in the lumen of the ileum and large intestine is not limited by the method of administration of said composition. The term "administration" in this context relates to the manner and form in which said composition first comes into contact with the patient's body. This means that said composition in a suitable form can be administered orally, rectally, or in any other way that results in the accumulation of said composition at the local administration site.
[0069] In the present invention, the term "localized treatment in the ileum and / or large intestine" refers to localized administration in the lumen of the ileum and / or large intestine, as defined above, in other words, anywhere within the connected, continuous interior formed by the ileum and large intestine of the small intestine. The "large intestine" is the last part of the gastrointestinal (GI) tract and can be further subdivided into the cecum, colon, and rectum. The "colon" can be further subdivided into the ascending colon, transverse colon, and descending colon. The "ileum" of the small intestine is the last part of the small intestine, which is connected at one end to the cecum. The "terminal ileum" is the last part of the ileum immediately adjacent to the cecum. The term "gastrointestinal tract" or "GI" as used herein includes all structures between the mouth and the anus, forming a continuous passageway, and refers to the system of human body organs that function to digest ingested material, absorb nutrients, and expel feces. In one embodiment of the present invention, the composition of the present invention is for use in localized treatment in the terminal ileum and / or large intestine, preferably the colon. In another embodiment of the invention, the compositions of the invention are for use in the localized treatment of the terminal ileum, cecum, ascending colon, transverse colon, and / or descending colon of a patient.
[0070] Local treatment with the pharmaceutical composition of the present invention allows local administration of the TNFα antibody and its functional fragments or derivatives in the lumen of the ileum and / or colon of the patient. Systemic administration of the TNFα antibody and its functional fragments or derivatives can thereby be avoided. In this way, systemic absorption and distribution of the TNFα antibody and its functional fragments or derivatives can be minimized. Thus, the TNFα antibody and its functional fragments or derivatives do not significantly counteract the success of cancer treatment with ICP inhibitors at the systemic level. Furthermore, a number of risks associated with systemic inhibition of the immune defense function of TNFα in patients can be minimized, including infectious complications and the accumulation of antibodies specific to anti-TNFα antibodies in the patient's body, resulting in loss of response to anti-TNFα antibodies.
[0071] According to a first aspect of the invention, the composition of the invention is for use in the treatment of a patient suffering from an ICP inhibitor induced adverse event in the ileum and / or colon, i.e. ICP inhibitor induced diarrhea, colitis or enteritis.
[0072] As used herein, an "ICP inhibitor" is any molecule (e.g., a small molecule, protein, peptide, nucleic acid molecule, or antibody) that is administered to a patient to stimulate the patient's immune system (e.g., by unblocking an existing immune response or unblocking the initiation of an immune response) to treat a disease (e.g., cancer or infectious disease). An ICP inhibitor may target any component immune checkpoint known in the art that results in stimulation of the immune system. This includes, but is not limited to, CTLA-4, PD-1, PD-L1, PDL2, B7-H3, B7-H4, BTLA, HVEM, TIM3, GAL9, LAG3, CSF-1R, VISTA, KIR, 2B4, CD160, CGEN-15049, CHK1, CHK2, A2aR, ADAR1, CD47 (target of CD47 inhibitors), ICOS (target of ICOS agonists), TIGIT (target of TIGIT inhibitors), and the B-7 family of ligands. Inhibitors against a single component of the immune checkpoint or a combination of different inhibitors against different components of the immune checkpoint may be used. Immune checkpoints are usually part of or consist of inhibitory or stimulatory pathways that maintain self-tolerance and support the immune response. ICP inhibitors according to the present invention include molecules that block pathways and molecules that stimulate pathways. For example, TIGIT inhibitors and ICOS agonists are ICP inhibitors in the sense of the present invention. Journal of Hematology & Oncology 11, article number 39 (2018) by Marin-Acevedo et al. summarizes inhibitory and stimulatory pathways and their targets that suitable ICP inhibitors can target. The contents of Marin-Acevedo et al. are incorporated herein in their entirety.
[0073] As used herein, an "adverse event" is an unfavourable, generally unintended or even undesirable sign (including abnormal laboratory findings), symptom or disease associated with the use of a medical treatment. For example, an adverse event may be associated with activation of the immune system or expansion of immune system cells (e.g., T cells) in response to the treatment. A medical treatment may have one or more associated adverse events. Also, the severity of each adverse event may be the same or different.
[0074] As used herein, "colitis" in the context of the present invention refers to an inflammatory condition of the large intestine, particularly the colon, which may be associated with symptoms such as diarrhea, abdominal pain, nausea, cramps, bloody or mucus in the stool, or changes in bowel habits, fever, abdominal distension, constipation, and an edemic, hyperemic, and / or fragile wall of the large intestine.As used herein, "colitis" in the context of the present invention refers to an inflammatory condition of the large intestine, particularly the colon, and the ileum of the small intestine, preferably the terminal ileum, which may be associated with symptoms such as diarrhea, abdominal pain, nausea, cramps, bloody or mucus in the stool, or changes in bowel habits, fever, abdominal distension, constipation, or an edemic, hyperemic, and / or fragile wall of the ileum or large intestine.
[0075] As used herein, the terms "ICP inhibitor-induced colitis" and "ICP inhibitor-induced enteritis" refer to colitis and enteritis, respectively, that (1) first occurs in a patient concurrently with or some time thereafter (i.e., days or weeks, e.g., 1-60 weeks, 1-48 weeks, 13-60 weeks, or 7-26 weeks) after the first dose of one or more ICP inhibitors, (2) is diagnosed by a physician as ICP inhibitor-induced colitis or enteritis, respectively, based on criteria set forth in the ASCO practice guidelines, and (3) is not diagnosed by a physician as colitis or enteritis, respectively, of a different etiology (e.g., Clostridium difficile toxins).
[0076] Unless otherwise noted, the terms "patient" or "subject" are used interchangeably and refer to mammals, such as human patients and non-human primates, as well as laboratory animals, such as rabbits, rats, and mice, and other animals. Animals include all vertebrates, including mammals (e.g., sheep, dogs, cows, chickens) and non-mammals, amphibians, and reptiles.
[0077] In living patients, ICP inhibitor-induced colitis may be classified into grades 1-4 based on the toxicity occurring in the large intestine, particularly the colon, resulting from treatment with one or more ICP inhibitors in the patient. The grading of ICP inhibitor-induced colitis is as follows: Grade 1 colitis presents asymptomatically with only radiographic or histologic findings. Grade 2 colitis is characterized by the presence of mucus or blood in the stool and abdominal pain. Grade 3 colitis is characterized by severe abdominal pain, fever, changes in bowel habits, and peritoneal signs. Grade 4 colitis is a life-threatening condition characterized by signs of perforation, hemorrhage, ischemia, necrosis, and the development of toxic megacolon. Grade 5 colitis is death due to colitis.
[0078] Similarly, ICP inhibitor-induced enterocolitis may be classified as grades 1 to 4 based on the toxicity occurring in the small intestine, particularly the ileum and large intestine, resulting from treatment of a patient with one or more ICP inhibitors. The classification of ICP inhibitor-induced enterocolitis is as follows: Grade 1 enteritis presents asymptomatic with only radiographic or histologic findings. Grade 2 enteritis is characterized by the presence of mucus or blood in the stool and abdominal pain. Grade 3 enteritis is characterized by severe or persistent abdominal pain, fever, intestinal obstruction, and peritoneal signs. Grade 4 enterocolitis is a life-threatening condition characterized by signs of perforation, hemorrhage, ischemia, necrosis, and the development of toxic megacolon. Grade 5 enteritis is death due to enteritis.
[0079] ICP inhibitor-induced diarrhea is classified as follows: Grade 1 diarrhea is defined as an increase of less than four stools above baseline. Grade 2 diarrhea is characterized by 4 to 6 stools above baseline. Grade 3 diarrhea is characterized by 7 or more stools above baseline. Grade 4 diarrhea is characterized by a life-threatening condition due to diarrhea. Grade 5 diarrhea is fatal.
[0080] The diagnostic workup to determine the grade of toxicity of ICP inhibitor-induced diarrhea, colitis, or enteritis can be performed, for example, as described in the ASCO practice guideline (Brahmer et al., "Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy": American Society of Clinical Oncology Practice Guideline, J Clin Oncol. 2018 Jun 10;36(17):1714-1768). According to the ASCO practice guideline, the diagnostic workup for grade 2 toxicity should include: - A blood (CBC, comprehensive metabolic panel, thyroid-stimulating hormone [TSH], erythrocyte sedimentation rate [ESR], C-reactive protein [CRP]) and stool (culture, Clostridium difficile, parasites, cytomegalovirus [CMV] or other viral etiology, ova and parasites) workup should be performed; - Lactoferrin may be tested for patient stratification to determine who needs urgent endoscopy, and calprotectin may be offered for follow-up of disease activity; - Screening tests to prepare for the initiation of infliximab in patients (blood quantiferon for HIV, hepatitis A and B, tuberculosis) should be routinely performed in patients at high risk for these infections and in appropriately selected patients based on the evaluation of an infectious disease specialist; - Imaging with computed tomography (CT) scan of the abdomen and pelvis and gastrointestinal endoscopy with biopsy may be performed, as there is evidence that the presence of colonic ulcers can predict a corticosteroid-refractory course. Infliximab or other tumor necrosis factor (TNF) blockers should not be delayed pending the results of these screening tests. - Patients who do not respond to immunosuppressants may undergo repeat endoscopy. Repeat endoscopy for disease monitoring should only be offered when clinically indicated and when resumption of treatment is planned.
[0081] According to the ASCO practice guideline, the diagnostic workup for grade 3-4 toxicity should include: - All workups (blood, stool, imaging, and biopsy) for grade 2 cases above must be completed immediately. - Patients who do not respond to immunosuppressants may have repeat endoscopy. Repeat endoscopy for disease monitoring should only be offered if clinically indicated and if resumption of ICP inhibitors is planned.
[0082] According to one embodiment of the invention, treatment with said antibody or a fragment or derivative thereof prevents the progression of side effects (e.g. diarrhea, colitis and / or enteritis) to higher grade toxicity. The following embodiments are preferred:
[0083] The treated patient suffers from a grade 1 toxic side effect (e.g., diarrhea, colitis and / or enteritis) and treatment with the antibody or fragment or derivative thereof prevents the side effect from progressing to a higher grade of toxicity, e.g., grade 2 toxicity.
[0084] The treated patient suffers from a grade 2 toxic side effect (e.g., diarrhea, colitis and / or enteritis) and treatment with the antibody or fragment or derivative thereof prevents the side effect from progressing to a higher grade toxicity, e.g., grade 3 toxicity.
[0085] The treated patient suffers from a grade 3 toxic side effect (e.g., diarrhea, colitis and / or enteritis), and treatment with the antibody or fragment or derivative thereof prevents the side effect from progressing to a higher grade of toxicity, e.g., grade 4 toxicity.
[0086] In one aspect, the present invention relates to an active agent selected from the group consisting of antibodies specific for tumor necrosis factor alpha (TNFα) and functional fragments and derivatives thereof, for use in preventing the progression or worsening of at least one adverse event of the gastrointestinal tract induced by cancer therapy in a patient, preferably induced by one or more immune checkpoint (ICP) inhibitors, wherein said prevention comprises local administration of said composition to the ileum and / or colon of said patient. Preferably, said local administration is oral administration. Preferably, said adverse event is selected from the group consisting of diarrhea, colitis, enteritis, and combinations thereof. Also, progression from grade 1 toxicity to grade 2 toxicity or higher is prevented. In another embodiment, said adverse event is selected from the group consisting of diarrhea, colitis, enteritis, and combinations thereof. Also, progression from grade 2 toxicity to grade 3 toxicity or higher is prevented. In another embodiment, said adverse event is selected from the group consisting of diarrhea, colitis, enteritis, and combinations thereof. Also, progression from grade 3 toxicity to grade 4 toxicity or higher is prevented. Preferred embodiments of this aspect of the invention correspond mutatis mutandis to preferred embodiments of the other aspects of the invention described herein.
[0087] According to another embodiment of the invention, a patient treated with the antibody or fragment or derivative thereof suffers from ICP inhibitor induced diarrhea but does not suffer from colitis or enteritis, and said treatment prevents the progression or onset of colitis and enteritis in said patient.
[0088] According to one embodiment of the first aspect of the present invention, the patient is also receiving treatment with one or more ICP inhibitors. "Also receiving treatment with one or more ICP inhibitors" means that the treatment has not been finally discontinued, but is currently ongoing or temporarily interrupted. According to a preferred embodiment, the patient is also receiving systemic treatment with one or more ICP inhibitors. Systemic treatment or treatment refers to a treatment that reaches and affects substantially all cells of the body via the systemic circulation.
[0089] Prior to administering the compositions of the present invention, treatment with one or more ICP inhibitors may be interrupted for weeks or days, or not at all, upon the occurrence of ICP inhibitor-induced diarrhea, colitis, or enteritis-related toxicity. According to one embodiment of the present invention, treatment with one or more ICP inhibitors is interrupted for less than 4 weeks, preferably less than 2 weeks, more preferably 1 week, even more preferably less than 5, 4, 3, 2, or 1 day, and most preferably the treatment is not interrupted.
[0090] The toxicity grade of the patient suffering from ICP inhibitor-induced diarrhea, colitis or enteritis to which the composition of the present invention is administered is not particularly limited. The toxicity grade of ICP inhibitor-induced diarrhea, colitis or enteritis may be diagnosed by a physician, for example, by applying the ASCO practice guidelines. In one embodiment, the patient suffers from ICP inhibitor-induced diarrhea, colitis or enteritis of toxic level 1 or higher. In another embodiment, the patient suffers from ICP inhibitor-induced diarrhea, colitis or enteritis of toxic level 2 or higher. In yet another embodiment, the patient suffers from ICP inhibitor-induced diarrhea, colitis or enteritis of toxic level 3 or higher. In a further embodiment, the patient suffers from ICP inhibitor-induced diarrhea, colitis or enteritis of toxic level 4.
[0091] According to a preferred embodiment, the compositions of the invention are for use as a first line treatment for patients with ICP inhibitor induced diarrhea, colitis or enteritis in place of steroidal immunosuppressants such as systemic corticosteroids, hi one embodiment, said patients are not and have not been treated with corticosteroids.
[0092] In an alternative embodiment, the patient is first treated with a steroid immunosuppressant (e.g., a corticosteroid such as prednisone, prednisolone, methylprednisolone, dexamethasone, or budesonide), and the composition of the present invention is administered to the patient only if the ICP inhibitor-induced diarrhea, colitis, or enteritis is resistant to steroid treatment. As used herein, the terms "resistant to steroid treatment" and "steroid-resistant diarrhea, colitis, or enteritis" refer to diarrhea, colitis, or enteritis induced by one or more ICP inhibitors that does not respond to steroid treatment. Thus, according to certain alternative embodiments, the composition of the present invention is for use as a second-line treatment for patients with steroid-resistant ICP inhibitor-induced diarrhea, colitis, or enteritis.
[0093] In a particular embodiment, the pharmaceutical composition of the present invention is administered in a maintenance therapy. That is, the composition is administered to prevent the recurrence of an adverse event (diarrhea, colitis and / or enteritis). If the adverse event is successfully treated, the composition may be continued to be administered to prevent its recurrence. The maintenance dose of the active agent may be lower than the dose used to treat the adverse event.
[0094] Furthermore, in a second aspect, the present invention relates to a pharmaceutical composition comprising an active agent selected from the group consisting of antibodies specific for TNFα and functional fragments or derivatives thereof, for use in localized treatment in the ileum and / or large intestine of a patient as a preventative treatment of ICP inhibitor-induced diarrhea, colitis or enteritis. With regard to the terms "antibodies specific for TNFα and functional fragments or derivatives thereof", "localized treatment in the ileum and / or large intestine" and "ICP inhibitor-induced diarrhea, colitis or enteritis", please see the detailed explanation above.
[0095] The term "prophylactic treatment" as used in the context of the present invention refers to administering an active agent as a preventative treatment. The term "prophylactic treatment of ICP inhibitor-induced diarrhea, colitis or enteritis" as used in the context of the present invention refers to administering a composition of the present invention prior to the onset of symptoms associated with ICP inhibitor-induced diarrhea, colitis or enteritis as a preventative or semi-prophylactic treatment.
[0096] The compositions of the invention for use as a localized treatment in the ileum and / or colon of a patient as a prophylactic treatment allow for simultaneous systemic treatment with one or more ICP inhibitors. "Concurrently" in the context of the present invention refers to a treatment regimen in which said patient receives simultaneous treatment with one or more ICP inhibitors.
[0097] In a preferred embodiment of the present invention, the patient is simultaneously undergoing treatment with one or more ICP inhibitors. In another preferred embodiment, the patient is simultaneously undergoing systemic treatment with one or more ICP inhibitors. For this purpose, the one or more ICP inhibitors may be administered simultaneously as part of a separate composition, at the same administration frequency as the composition of the present invention, or at different times and / or at different administration frequencies. Furthermore, the one or more ICP inhibitors may be administered via the same administration route or via different administration routes. With regard to the administration route of the ICP inhibitor, please refer to the description of the ICP inhibitor below.
[0098] For example, the one or more ICP inhibitors may be administered intravenously or via subcutaneous or intramuscular injection, while the composition of the present invention may be administered orally or rectally. Alternatively, both the one or more ICP inhibitors and the composition of the present invention may be administered orally or rectally. When the one or more ICP inhibitors and the composition of the present invention are administered via the same administration route with the same administration frequency, the one or more ICP inhibitors may be added to the composition of the present invention as an additional active agent.
[0099] By administering the composition of the present invention as a preventative treatment, the onset of symptoms associated with ICP inhibitor-induced diarrhea, colitis or enteritis can be delayed and / or minimized, or even prevented. Thus, in one embodiment, the composition of the present invention for use in localized treatment in the ileum and / or large intestine of a patient as a preventative treatment of ICP inhibitor-induced diarrhea, colitis or enteritis prevents, minimizes, and / or delays symptoms associated with ICP inhibitor-induced diarrhea, colitis or enteritis. In a preferred embodiment, the patient suffers from ICP inhibitor-induced diarrhea. The onset of symptoms associated with ICP inhibitor-induced colitis or enteritis can be delayed and / or minimized, or even prevented. Thus, the composition of the present invention for use in localized treatment in the ileum and / or large intestine of a patient as a preventative treatment of ICP inhibitor-induced colitis or enteritis prevents, minimizes, and / or delays symptoms associated with ICP inhibitor-induced colitis or enteritis.
[0100] In another embodiment, the compositions of the invention for use in localized treatment in the ileum and / or large intestine of a patient as a prophylactic treatment of ICP inhibitor induced diarrhea, colitis or enteritis prevent the onset of ICP inhibitor induced diarrhea, colitis or enteritis. In yet another embodiment, the compositions of the invention for use in localized treatment in the ileum and / or large intestine of a patient as a prophylactic treatment of ICP inhibitor induced diarrhea, colitis or enteritis prevent the onset of one or more symptoms associated with ICP inhibitor induced diarrhea, colitis or enteritis.
[0101] In an alternative embodiment, the composition of the invention for use in localized treatment in the ileum and / or colon of a patient as a prophylactic treatment of ICP inhibitor-induced diarrhea, colitis or enteritis delays the onset and / or minimizes the severity of one or more symptoms associated with ICP inhibitor-induced diarrhea, colitis or enteritis. According to a particular embodiment, said localized treatment prevents the progression of grade 3 toxicity, preferably grade 2 toxicity, more preferably grade 1 toxicity, and most preferably the onset of any symptoms associated with ICP inhibitor-induced diarrhea, colitis or enteritis in said patient.
[0102] Use of the compositions of the present invention for localized treatment in the ileum and / or large intestine of a patient with ICP inhibitor-induced diarrhea, colitis or enteritis, or for prophylactic treatment of ICP inhibitor-induced diarrhea, colitis or enteritis, in lieu of the standard treatment regimens recommended in ASCO clinical practice guidelines, etc., reduces the incidence and / or severity of symptoms of ICP inhibitor-induced diarrhea, colitis or enteritis associated with use of the standard treatment regimens for ICP inhibitor-induced diarrhea, colitis or enteritis.
[0103] In certain embodiments, the treatment of the present invention is associated with or leads to an increase in overall patient survival compared to patients not treated according to the present invention. Preferably, the treatment of the present invention is associated with or leads to an increase in overall patient survival compared to patients treated with corticosteroids. The treatment of the present invention is associated with or may lead to an increase in overall patient survival compared to patients not treated according to the present invention or with corticosteroids.
[0104] The present invention is advantageous in that it may not require the administration of corticosteroids, which often lead to an increased rate of infection, necessitating the administration of antibiotics. The present invention allows for the avoidance of corticosteroids and antibiotics. Thus, in a preferred embodiment, the composition of the present invention is administered after the first signs of enteritis, colitis, and / or diarrhea are detected.
[0105] The present invention further provides for the prophylactic use of the compositions described herein. Thus, in another embodiment, the compositions of the present invention are administered before symptoms of enteritis, colitis and / or diarrhea are detectable or are detected. In another embodiment, the compositions of the present invention are administered to a patient, preferably a cancer patient, more preferably a cancer patient treated with at least one ICP inhibitor. Wherein the patient has not been diagnosed as suffering from enteritis, colitis and / or diarrhea. In another embodiment, the compositions of the present invention are administered to a patient, preferably a cancer patient, more preferably a cancer patient treated with at least one ICP inhibitor. Wherein the patient does not suffer from enteritis, and / or the patient does not suffer from colitis; and / or the patient does not suffer from diarrhea. The patient may be at risk of developing enteritis, colitis and / or diarrhea. The patient may be suspected of developing enteritis, colitis and / or diarrhea. The present invention relates to the use of the compositions described herein for preventing the onset or progression of enteritis, colitis and / or diarrhea in a patient, preferably a cancer patient, more preferably a cancer patient being treated with at least one ICP inhibitor.
[0106] In certain embodiments, administration of the active agent improves the efficacy of treatment with an ICP inhibitor.
[0107] ICP inhibitors can be administered to patients to treat diseases such as cancer or prevent the recurrence of such diseases. Such treatments almost always cause ICP inhibitor-induced adverse events at some point. Among the most frequent adverse events are ICP inhibitor-induced adverse events in the gastrointestinal tract, such as inhibitor-induced diarrhea, colitis or enteritis.
[0108] "Cancer" refers to a broad group of diseases characterized by the uncontrolled growth of abnormal, usually endogenous, cells in the body. Uncontrolled cell division and proliferation can lead to the formation of malignant tumors that invade adjacent tissues and may metastasize to distant parts of the body via the lymphatic system or bloodstream. The terms "cancer," "tumor," and "neoplasm" are used interchangeably herein.
[0109] Cancers that can be treated with ICP inhibitors are not particularly limited. Exemplary cancers that can be treated with ICP inhibitors include, but are not limited to, melanoma, lymphomas such as classical Hodgkin's lymphoma, glioma, urothelial cancer, renal cancer, squamous cell carcinoma of the head and neck, prostate cancer, breast cancer, colon cancer, and lung cancer. According to one embodiment of the present invention, the one or more ICP inhibitors are used to treat bone cancer, pancreatic cancer, skin cancer, head and neck cancer, cutaneous or intraocular malignant melanoma, uterine cancer, ovarian cancer, rectal cancer, anal cancer, gastric cancer, testicular cancer, uterine cancer, fallopian tube cancer, endometrial carcinoma, cervical carcinoma, vaginal carcinoma, vulvar carcinoma, Hodgkin's disease, non-Hodgkin's lymphoma, esophageal cancer, small intestine cancer, cancer of the endocrine system, thyroid cancer, parathyroid cancer, adrenal cancer, soft tissue sarcoma, urethral cancer, penile cancer, chronic or acute leukemia, acute myeloid leukemia, chronic It is used to treat cancers selected from the group consisting of myeloid leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia, solid tumors of childhood, lymphocytic lymphoma, bladder cancer, cancer of the kidney or ureter, cancer of the renal pelvis, neoplasms of the central nervous system (CNS), primary CNS lymphoma, tumor angiogenesis, spinal tumors, brain stem glioma, pituitary adenoma, Kaposi's sarcoma, epidermoid carcinoma, squamous cell carcinoma, T-cell lymphoma, environmentally induced cancers including those induced by asbestos, and combinations of these cancers.
[0110] ICP inhibition can be performed on various ICP components, including, for example, PD-1, PD-L1, CTLA-4, LAG-3, ADAR1 and TIM-3, as well as combinations of such ICP components, for example by inhibiting (blocking) the components of the ICP. The ICP components may be, for example, but not limited to, receptors or ligands on tumor cells or immune cells (such as T cells, monocytes, microglia, and macrophages). The ICP inhibitor need not be an antibody, but may be a small molecule or other polymer. When the ICP inhibitor is an antibody, it may be a polyclonal, monoclonal, fragment, single chain, or other antibody variant construct. ICP inhibitors include, for example, anti-PD-1 antibodies, anti-PD-L1 antibodies, anti-CTLA-4 antibodies, anti-LAG-3 antibodies, and anti-TIM-3 antibodies.
[0111] The ICP inhibitor may target any component of the ICP known in the art to provide stimulation of the immune system. This includes, but is not limited to, CTLA-4, PD-1, PD-L1, PDL2, B7-H3, B7-H4, BTLA, HVEM, TIM3, GAL9, LAG3, CSF-1R, VISTA, KIR, 2B4, CD160, CGEN-15049, CHK1, CHK2, A2aR, ADAR1, TIGIT, CD47, ICOS, and the B-7 family of ligands. Inhibitors directed against a single target component of the ICP or a combination of different inhibitors directed against different target components of the ICP may be used.
[0112] The ICP inhibitor may be administered simultaneously with, before, or after the pharmaceutical composition of the present invention.The ICP inhibitor may be administered by any suitable method known in the art for a particular inhibitor that allows the treatment of a particular cancer or infectious disease.Usually, the ICP inhibitor is administered systemically.Suitable methods known in the art for administering the ICP inhibitor include, for example, intravenous, oral, intraperitoneal, sublingual, intrathecal, intracavity, intramuscular, and subcutaneous administration.
[0113] Preferred routes of administration of the one or more ICP inhibitors include intravenous, intramuscular, intradermal, intraperitoneal, subcutaneous, spinal, or other parenteral routes of administration, for example, by injection or infusion. The term "parenteral administration" as used herein refers to modes of administration other than enteral and topical administration, usually by injection, and includes, but is not limited to, intravenous, intramuscular, intraarterial, intrathecal, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcutaneous, intraarticular, subcapsular, subarachnoid, intraspinal, epidural, and intrapedicular injection and infusion. In a more preferred embodiment of the present invention, the one or more ICP inhibitors are administered intravenously. Alternatively, the one or more ICP inhibitors may be administered via a route of parenteral administration, such as a topical, epidermal, or mucosal route of administration (e.g., an intranasal, oral, vaginal, rectal, sublingual, or topical route of administration).
[0114] Currently available ICP inhibitors include antibodies specific for CTLA-4, PD-1, and PD-L1. According to one embodiment of the present invention, the one or more ICP inhibitors are selected from the group consisting of antibodies specific for CTLA-4, antibodies specific for PD-1, and antibodies specific for PD-L1. Monoclonal antibodies specific for, and thus targeted to, either PD-1 or PD-L1 can block the binding between these two ICP components and enhance the immune response against cancer cells. These drugs have shown considerable promise in the treatment of various types of cancer.
[0115] Examples of PD-1 specific antibodies currently used as ICP inhibitors in cancer therapy include the monoclonal antibodies pembrolizumab (Keytruda®) and nivolumab (Opdivo®). These antibodies have been shown to be effective in treating several types of cancer, including melanoma of the skin, non-small cell lung cancer, kidney cancer, bladder cancer, head and neck cancer, and Hodgkin's lymphoma.
[0116] Examples of PD-L1 specific antibodies currently used as ICP inhibitors in cancer treatment include the monoclonal antibodies atezolizumab (Tecentriq®), avelumab (Bavencio®), and durvalumab (Imfinzi®). These antibodies have also been shown to be effective in treating various types of cancer, including bladder cancer, non-small cell lung cancer, and Merkel cell skin cancer (Merkel cell carcinoma).
[0117] CTLA-4 is another B7-CD28 family member that inhibits T cell function. It is constitutively expressed by regulatory T cells, but upon activation, it inhibits other T cell types, especially CD4 +It can also be upregulated by T cells. CTLA-4 mediates immune suppression by indirectly reducing signaling through the costimulatory receptor CD28. CTLA-4 signaling has been shown to dampen immune responses to infections and tumor cells (Curran MA et al., Proc Natl Acad Sci US A. 2010 Mar. 2; 107(9):4275-80). Examples of antibodies specific for CTLA-4 that are currently being used or investigated as ICP inhibitors in cancer therapy include the monoclonal antibodies ipilimumab (Yervoy®) and tremelimumab (Pfizer), respectively.
[0118] According to one embodiment of the invention, the one or more ICP inhibitors are a combination of an antibody specific for PD-1 and / or PD-L1 and an antibody specific for CTLA-4, preferably a combination of an antibody specific for PD-1 or PD-L1 and an antibody specific for CTLA-4. According to another embodiment of the invention, the antibody specific for PD-1 is selected from the group consisting of pembrolizumab and nivolumab, the antibody specific for PD-L1 is selected from the group consisting of atezolizumab, avelumab, and durvalumab, and the antibody specific for CTLA-4 is selected from the group consisting of ipilimumab and tremelimumab. According to another embodiment of the invention, the patient treated with the composition of the invention suffers from ICP inhibitor-induced diarrhea, colitis or enteritis caused by treatment with any one or more of the above ICP inhibitors.
[0119] For administration of antibodies specific for CTLA-4, PD-1 and PD-L1, a dosage range of, for example, about 0.0001-100 mg per kg patient weight, preferably 0.01-5 mg per kg patient weight, is appropriate. Exemplary dosages may be within the range of 0.3 mg / kg body weight, 1 mg / kg body weight, 3 mg / kg body weight, 5 mg / kg body weight, or 10 mg / kg body weight, or 1-10 mg / kg body weight. The antibodies are usually administered repeatedly. Exemplary dosing regimes call for administration once a week, once every two weeks, once every three weeks, once every four weeks, once a month, once every three months, once every three to six months, or once every six months. The intervals may be irregular, depending on the measurement of blood levels of antibodies against the target antigen in the patient. In some cases, the dosage is adjusted to achieve a particular plasma antibody concentration, for example, about 1-1000 μg / ml or about 25-300 μg / ml.
[0120] Preferred dosing regimens for CTLA-4, PD-1 or PD-L1 specific antibodies include, but are not limited to, about 1-10 mg / kg body weight, administered intravenously, of one antibody or a combination of antibodies (i) every 4 weeks for six doses, followed by every 3 months; (ii) every 3 weeks; (iii) every 2 weeks; or (iv) every week.
[0121] As used herein, "about" means within an acceptable error range of a particular value as measured by a person skilled in the art, which depends in part on how the value is measured or measured, i.e., on the limitations of the measurement system. For example, "about" can mean within one or more standard deviations, per the practice in the art. Alternatively, "about" can mean within a range of up to 20%. Furthermore, particularly with respect to biological systems or processes, the term can mean values up to an order of magnitude or up to 5 times.
[0122] In some cases, two or more CTLA-4, PD-1, and / or PD-L1 specific antibodies are administered simultaneously. In this case, the dosage of each antibody administered may be within the dosage ranges described above. When multiple CTLA-4, PD-1, or PD-L1 specific antibodies are administered, each may have a different binding specificity for CTLA-4, PD-1, or PD-L1.
[0123] Alternatively, the ICP inhibitor antibody can be administered as a sustained release formulation, which requires less frequent administration. The dosage and frequency of administration will depend on the half-life of the antibody in the patient. In general, human antibodies exhibit the longest half-life, followed by humanized antibodies, chimeric antibodies, and non-human antibodies.
[0124] ADAR1 is an RNA editing enzyme that catalyzes the hydrolytic deamination of adenosine to inosine in double-stranded RNA (UniProt No. P55265). The function of ADAR1 can be inhibited by gene silencing techniques using antibodies against ADAR1 and their functional fragments, or siRNA, etc.
[0125] In a patient undergoing treatment with one or more ICP inhibitors, the one or more ICP inhibitors may modulate the immune response in the patient and / or it may inhibit the growth of tumor cells in the patient.
[0126] The patient treated with the composition of the present invention may be a cancer patient.In one embodiment, the patient is a cancer patient and is undergoing or has undergone treatment with one or more ICP inhibitors, preferably one or more ICP inhibitors as described above.Preferably, the cancer patient is undergoing treatment with one or more ICP inhibitors.Preferably, the treatment with one or more ICP inhibitors is a systemic treatment.
[0127] In certain embodiments, the patient is undergoing treatment with a cancer vaccine. For example, the patient may be undergoing combination treatment with an ICP inhibitor and a cancer vaccine.
[0128] As used herein, the term "cancer vaccine" has its general meaning in the art and refers to a composition capable of inducing active immunity against at least one cancer antigen. A cancer vaccine typically includes a source of cancer-related material or cells (antigens), which may be autologous or allogeneic to the subject, along with other components (e.g., adjuvants) to further stimulate and enhance the immune response to the antigen. A cancer vaccine can stimulate the subject's immune system to produce antibodies against one or several specific antigens and / or to produce killer T cells to attack cancer cells bearing those antigens. A cancer vaccine can result in the production of antibodies or simply the activation of specific cells, particularly antigen-presenting cells, T lymphocytes (especially T-CD8+ cells) and B lymphocytes. A cancer vaccine can be a composition for prophylactic or therapeutic purposes, or both.
[0129] There are several types of cancer vaccines, non-limiting examples of which include tumor cell vaccines, antigen vaccines, dendritic cell vaccines, DNA vaccines, and vector-based vaccines.
[0130] Typically, the cancer vaccine of the present invention comprises a tumor-associated antigen or a nucleic acid sequence (e.g., DNA) encoding the tumor-associated antigen. Many tumor-associated antigens are known in the art. Exemplary tumor-associated antigens include 5α-reductase, α-fetoprotein, AM-1, APC, April, BAGE, β-catenin, Bell 2, bcr-abl, CA-125, CASP-8 / FLICE, cathepsin, CD 19, CD20, CD21, CD23, CD22, CD33 CD35, CD44, CD45, CD46, CD5, CD52, CD55, CD59, CDC27, CDK4, CEA, c-myc, Cox-2, DCC, DcR3, E6 / E7, CGFR, EMBP, Dna78, farnesyltransferase, FGF8b, FGF8a, FLK-1 / KDR, folate receptor, G250, GAGE family, gastrin-17, gastrin-releasing hormone, GD2 / GD3 / GM2, GnRH, GnTV, GP1, hCG, heparanase, Her2 / neu, HMTV, Hsp70, hTERT, IGFR1, IL-13R, iNOS, Ki67, KIAA0205, K-ras, H-ras, N-ras, KSA, LKLR-FUT, MAGE family, mammaglobin, MAP 17, melan-A / MART-1, mesothelin, MIC AB, MT-MMP, mucin, NY-ESO-1, osteonectin, P170 / MDR1, p53, p97 / melanotransferrin, PAI-1, PDGF, uPA, PRAME, probasin, progenipoentin, PSA, PSM, RAGE-1, Rb, RCAS1, SART-1, SSX family, STAT3, STn, TAG-72, TGF-α, TGF-β, thymosin-β-15, TNF-α, TYRP-, TYRP-2, tyrosinase, VEGF, and glutathione-S-transferase.
[0131] In some embodiments, the vaccine is a DNA vaccine. A vector can be genetically engineered to contain a specific DNA that can be injected into a subject. This allows the DNA to be incorporated into cells. Once the cells have incorporated the DNA, the DNA programs the cells to produce a specific antigen, which can trigger a desired immune response.
[0132] In some embodiments, the vaccine consists of a recombinant virus that encodes or expresses a cancer antigen, hi some embodiments, the recombinant virus is a poxvirus that expresses a tumor antigen, more specifically an orthopoxvirus, such as, but not limited to, vaccinia virus, modified vaccinia Ankara (MVA) virus, or MVA-BN.
[0133] In some embodiments, the vaccine composition comprises at least one population of antigen-presenting cells presenting a selected antigen. The antigen-presenting cells (or stimulator cells) typically have MHC class I or II molecules on their surface, and in one embodiment are themselves substantially incapable of loading the selected antigen onto MHC class I or II molecules. Preferably, the antigen-presenting cells are dendritic cells. Suitably, the dendritic cells are autologous dendritic cells pulsed with an antigen of interest (e.g., a peptide). T cell therapy using autologous dendritic cells pulsed with peptides from tumor-associated antigens is disclosed in Murphy et al. (1996) The Prostate 29, 371-380 and Tjua et al. (1997) The Prostate 32, 272-278. Thus, in some embodiments, the vaccine composition comprising at least one antigen-presenting cell is pulsed or loaded with one or more antigenic peptides. Alternatively, the antigen-presenting cells comprise an expression construct encoding an antigenic peptide. The polynucleotide may be any suitable polynucleotide. Preferably, this is capable of transducing dendritic cells, thus resulting in the presentation of the peptide and the induction of an immune response.
[0134] In some embodiments, the vaccine composition comprises one or more adjuvants. Adjuvants are substances that non-specifically increase or enhance immune responses (e.g., immune responses mediated by CD8 positive T cells and helper T cells to an antigen) and are therefore considered useful in the medicaments of the invention.
[0135] In a particular embodiment, the patient is a cancer patient suffering from a cancer selected from the group consisting of melanoma, lymphoma such as classical Hodgkin's lymphoma, glioma, urothelial carcinoma, renal cancer, squamous cell carcinoma of the head and neck, prostate cancer, breast cancer, colon cancer, lung cancer, and combinations thereof. In another particular embodiment, the cancer is bone cancer, pancreatic cancer, skin cancer, head and neck cancer, cutaneous or intraocular malignant melanoma, uterine cancer, ovarian cancer, rectal cancer, anal cancer, gastric cancer, testicular cancer, uterine cancer, fallopian tube cancer, endometrial cancer, cervical cancer, vaginal carcinoma, vulvar carcinoma, Hodgkin's disease, non-Hodgkin's lymphoma, cancer of the esophagus, cancer of the small intestine, cancer of the endocrine system, thyroid cancer, parathyroid cancer, adrenal cancer, soft tissue sarcoma, cancer of the urethra, cancer of the penis, chronic or acute leukemia, acute myeloid leukemia, chronic ... The cancer is selected from the group consisting of leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia, childhood solid tumors, lymphocytic lymphoma, bladder cancer, cancer of the kidney or ureter, renal pelvic cancer, neoplasms of the central nervous system (CNS), primary CNS lymphoma, tumor angiogenesis, spinal axis tumor, brain stem glioma, pituitary adenoma, Kaposi's sarcoma, epidermoid carcinoma, squamous cell carcinoma, T-cell lymphoma, environmentally induced cancers including those induced by asbestos, and combinations of the foregoing cancers.
[0136] According to the present invention, the composition of the present invention may be in any form that allows for localized treatment in the lumen of the ileum and / or the large intestine of a patient upon administration. The composition may be in a solid dosage form such as in the form of pellets, granules, microparticles, nanoparticles, minitablets, capsules, or tablets. Methods for producing solid dosage forms are known in the art, see, for example, Aulton, Pharmaceutics: Design and Manufacturing of Drugs, Churchill Livingstone title, 4th revised edition, 2013 (ISBN: 978-0-7020-4290-4). Specific examples of methods for the preparation of solid dosage forms comprising antibodies and functional fragments or derivatives include those disclosed in any of the international patent applications PCT / EP2018 / 074521, PCT / EP2018 / 07452, and PCT / EP2018 / 072524.
[0137] According to one embodiment, the composition of the present invention comprises at least one additive.Suitable additives include hydrophilic polymers, fillers, hydrophilic binders, disintegrants, anti-adhesives, surfactants, stabilizers, protease resistance enhancers, plasticizers, coalescents, lubricants, buffers, acidifiers and / or complexing agents.Suitable hydrophilic polymers, fillers, hydrophilic binders, disintegrants, anti-adhesives, surfactants, plasticizers, coalescents, lubricants, buffers and / or acidifiers are known to those skilled in the art.
[0138] In one embodiment of the present invention, the composition for use in the localized treatment of the ileum and / or large intestine is orally administered. Oral administration in the context of the present invention means introducing the composition into the gastrointestinal tract via the mouth. In a preferred embodiment of the present invention, the composition is in a solid dosage form, preferably in the form of pellets, granules, microparticles, nanoparticles, minitablets, spheres, capsules, tablets, or a multiparticulate drug delivery system coated with a delayed release coating. The term "delayed release" as used herein means that the release of the antibody or functional fragment or derivative thereof is prevented before the ileum, before the terminal ileum, before the ileocolic region, or before the colon of the intestine. The ileocolic region is the region of the gastrointestinal tract where the small intestine joins with the large intestine, i.e., the terminal ileum. In another embodiment, the composition is in a sustained release solid dosage form, preferably in the form of pellets, granules, microparticles, nanoparticles, minitablets, spheres, capsules, tablets, or a multiparticulate drug delivery system comprising a sustained release coating or sustained release matrix. In general, the term "sustained release" as used herein refers to a time-dependent release. That is, the antibody or functional fragment or derivative thereof is released over an extended period of time, such as at least 6 hours, preferably at least 8 hours, at least 10 hours, at least 12 hours, at least 14 hours, at least 16 hours, at least 18 hours, or at least 24 hours.
[0139] In a preferred embodiment, the composition comprises a sustained release core and a delayed release coating, in which the composition typically does not include a sustained release coating.
[0140] Preferably, the sustained release core is a non-ionic poly(ethylene oxide) polymer with a molecular weight of 100,000 to 7,000,000, HPMC having a viscosity of 3 to 100,000 mPa·s, preferably about 2,308 to 9,030 mPa·s, more preferably about 2,663 to 4,970 mPa·s, at 20° C. in water, at 2 wt.-%. and at least one sustained release agent selected from the group consisting of Type 2208, xanthan gum, guar gum, tragacanth gum, locust bean gum, acacia gum, chitosan, carbomer, ethylcellulose, polyvinyl acetate, glyceryl (di)behenate, glyceryl palmitostearate, polymethacrylic acid such as poly(ethyl acrylate, methyl methacrylate, trimethylammonioethyl methacrylate chloride) 1:2:0.1, poly(ethyl acrylate, methyl methacrylate, trimethylammonioethyl methacrylate chloride) 1:2:0.2, or poly(ethyl acrylate, methyl methacrylate) 2:1, and combinations thereof.
[0141] In another preferred embodiment, the composition comprises an immediate release core, a sustained release coating, and a delayed release coating, typically between the core and the delayed release coating.
[0142] In yet another embodiment, the composition comprises an immediate release core and a delayed release coating, but no sustained release coating.
[0143] Coating materials for delayed release of solid dosage forms, particularly for targeted release in the ileum or large intestine upon oral administration, are known in the art. They can be subdivided into coating materials that disintegrate above a certain pH, coating materials that disintegrate after a certain residence time in the gastrointestinal tract, and coating materials that disintegrate due to enzymatic triggers specific to the microflora of a certain region of the intestine. These three different categories of coating materials for targeting the large intestine are reviewed, for example, by Bansal et al. (Polim. Med. 2014, 44, 2, 109-118). These uses of such coating materials are also described, for example, in WO 2007 / 122374 A2, WO 01 / 76562 A1, WO 03 / 068196 A1, WO 2008 / 135090 A1 and GB 2367002 A. In one embodiment of the present invention, the delayed release coating comprises at least one component selected from a coating material that degrades with pH, a coating material that degrades with time, a coating material that degrades by an enzymatic trigger in the colonic environment, and combinations thereof.
[0144] Among the coating materials which disintegrate depending on the pH, preferred coating materials are selected from polyvinyl acetate phthalate, cellulose acetate trimellitate, hydroxypropyl methylcellulose phthalate HP-50, HP-55 or HP-55S, cellulose acetate phthalate, hydroxypropyl methylcellulose acetate succinate (HPMCAS), poly(methacrylic acid, ethyl acrylate) 1:1 (Eudragit® L100-55, Eudragit® L30D-55), poly(methacrylic acid, methyl methacrylate) 1:1 (Eudragit® L-100, Eudragit® L12.5), poly(methacrylic acid, methyl methacrylate) 1:2 (Eudragit® S-100, Eudragit® S12.5, Eudragit® FS30D), and combinations thereof. Among the coating materials that degrade over time, preferred coating materials are selected from poly(ethyl acrylate, methyl methacrylate) 2:1 (e.g. Eudragit® NM 30D, or Eudragit NE 30D), poly(ethyl acrylate, methyl methacrylate, trimethylammonioethyl chloride methacrylate) 1:2:0.1 (e.g. Eudragit® RS 30D), ethylcellulose (e.g. Surelease® or Aquacoat ECD); poly(ethyl acrylate, methyl methacrylate, trimethylammonioethyl chloride methacrylate) 1:2:0.2 (e.g. Eudragit® RL 30D); polyvinyl acetate (e.g. Kollicoat® SR 30D); and combinations thereof.Among the coating materials that degrade by enzymatic trigger in the environment of the large intestine, preferred coating materials are selected from chondroitin sulfate, pectin, guar gum, chitosan, inulin, lactulose, raffinose, stachyose, alginate, dextran, xanthan gum, locust bean gum, arabinogalactan, cyclodextrin, pullulan, carrageenan, scleroglucan, chitin, curdlan, levan, amylopectin, starch, amylose, resistant starch, azo compounds degraded by azo bond-degrading bacteria, and combinations thereof. The delayed release coating optionally comprises one or more further excipients.
[0145] In one embodiment of the invention, the coating material for the delayed release coating comprises one, two, three, etc. components selected from a pH-disintegrating coating material, a time-disintegrating coating material, a coating material that is degraded by an enzymatic trigger in the intestinal environment as described above, and combinations thereof. In another embodiment of the invention, the delayed release coating comprises a combination of at least one pH-disintegrating coating material and at least one enzymatically triggering coating material in the intestinal environment.
[0146] For example, a delayed release coating can be designed to focus delivery of the composition comprising the antibody or functional fragment or derivative thereof throughout the large intestine, starting at the cecum, continuing through the ascending, transverse, and descending colons, and ending at the sigmoid colon. Alternatively, for example, a delayed release coating can be designed to begin delivery of the antibody or functional fragment or derivative thereof in the ileum, and end its release in the transverse colon. The possibilities and combinations are numerous.
[0147] In a different embodiment of the invention, the composition for use in local treatment in the ileum and / or large intestine is administered rectally. Rectal administration in the context of the present invention means the introduction of said composition into the gastrointestinal tract via the anus. In a preferred embodiment of the invention, said composition is used in the form of an enema liquid, gel, foam or suppository.
[0148] Those skilled in the art can easily determine the effective amount of TNFα-specific antibody or functional fragment or derivative thereof to be administered as part of a composition for use according to the present invention.In general, the effective amount of TNFα-specific antibody or functional fragment or derivative thereof according to the present invention is the minimum amount required to produce a therapeutic effect, i.e., to treat diarrhea, colitis or enteritis induced by one or more ICP inhibitors.The exact amount of TNFα-specific antibody or functional fragment or derivative thereof to be administered to a patient may vary depending on the state and severity of the disorder and the physical condition of the patient.
[0149] According to one embodiment of the invention, the compositions of the invention provide a therapeutically effective amount of a TNFα-specific antibody or functional fragment or derivative thereof to the lumen of the ileum and / or large intestine of a patient to prevent, minimize, and / or delay or alleviate symptoms associated with ICP inhibitor-induced diarrhea, colitis or enteritis. A "therapeutically effective amount" is the amount of at least one TNFα-specific antibody or functional fragment or derivative thereof required to provide the desired therapeutic effect. The exact amount may vary for different antibodies or functional fragments or derivatives thereof, and / or for individual patients, but can be determined by one of skill in the art.
[0150] The therapeutically effective amount in the lumen of the ileum and / or large intestine can be achieved, for example, by targeting the composition of the present invention, which comprises an anti-TNFα antibody or a functional fragment or derivative thereof. The methods and means of targeting the composition of the present invention in the lumen of the ileum and large intestine are not particularly limited and can be achieved by methods known in the art. These include, for example, taking advantage of the innate processes of the gastrointestinal tract that result in differences in pH and microflora and specific residence times of ingested materials in various parts of the digestive tract. Methods for sampling the concentration of specific proteins, including specific antibodies, in the intestinal lumen are known in the art. Samples can be taken, for example, from excreted feces or using a flexible tube inserted through the anus. The concentration of TNFα antibodies can be measured using antibodies specific for the anti-TNF antibodies or functional fragments or derivatives used in the composition, using ELISA, Western blot, or other immunochemical techniques similar to those described by Nicholls et al. for measuring the concentration of TNFα in feces (J Clin Pathol. August 1993; 46(8):757-760).
[0151] A unit dose of the composition of the present invention may contain, for example, an amount of active agent in the range of about 0.05 mg to about 1,000 mg, 0.1 mg to about 200 mg, or about 1 mg to about 100 mg, or about 10 mg to about 50 mg.
[0152] The composition of the invention comprising a TNFα-specific antibody or functional fragment or derivative thereof can be administered to the patient, for example, once daily, twice daily, or three times daily. In a preferred embodiment, the composition is administered once daily. (Table 1) JPEG2024109837000001.jpg164144 EXAMPLES
[0153] Examples 1 and 2 Materials and Methods Used in the Examples
[0154] Preparation of citrate-TRIS buffer pH 7: 2.942 g of sodium citrate was made up to 100.0 mL with purified water to prepare a 100 mM sodium citrate solution. 3.842 g of citric acid was dissolved in purified water and diluted to 200.0 ml to prepare a 100 mM citric acid solution. The pH of the citric acid solution was adjusted to 3.5 with the sodium citrate solution. 12.114 g of TRIS was made up to 100.0 ml with purified water to prepare a 1M TRIS solution. The pH of the citrate buffer was adjusted to 7.0 with the TRIS solution.
[0155] 1. Preparation of Pellets Table 2: Formulation composition (pellet core) JPEG2024109837000002.jpg63148 * Values for dry mix before adding adalimumab
[0156] Preparation process: Dry blending: Using a Caleva Multilab mixer attachment (double paddle mixer), the excipients required for each batch (batch size: 10 g) were blended at 50 rpm for a given time of approximately 5 minutes. Wet blending: After the dry blending step, the Adalimumab solution containing 0.1% w / v Polysorbate 20 was slowly added to the excipient powder blend while mixing and mixed for 10 minutes at 50 rpm. Extrusion: The wet mass was then completely removed from the mixer and extruded using a screw extruder at a constant speed (150 rpm) through holes of 1 mm diameter and 1 mm depth until all the wet mass was extruded. Spheronization: The wet extrudate was then fed into a spheronizer attachment consisting of a grooved plate which, by rotating, cut the wet extrudate into smaller pieces and rounded (into wet spheres) depending on the time, speed and nature of the individual components of the extrudate. The extrudate was spheronized at 1500 rpm for a set period of time.
[0157] The wet pellets obtained from the spheronization step were then collected in a disposable weigh boat and dried overnight at 40° C. in a drying cabinet.
[0158] Delayed (Enteric) Release Coatings Adalimumab-containing pellets (from Examples 1 and 2) were coated with an enteric coating containing Eudragit L30D-55. The coating suspension was prepared by mixing the required amount of Eudragit L30D-55 dispersion with glyceryl monostearate (GMS) emulsion. The GMS emulsion was prepared by dissolving polysorbate 80 in water followed by the addition of GMS. The mixture was then heated to 75°C and maintained at that temperature for 15 minutes under continuous magnetic stirring. The cooled GMS emulsion was then added to the Eudragit L30D-55 followed by the addition of triethyl citrate (plasticizer). The suspension was stirred for 30 minutes before coating.
[0159] The coating suspension was then sprayed onto pellets containing adalimumab to achieve a target polymer loading of 30%. Coating was performed using a MiniGlatt fluid bed coater (bottom spray) equipped with a micro kit, allowing for coating of small batch sizes. Inlet temperature 40°C, product temperature 33.0-34.5°C, air flow 24-28 m 3 / h, and the Eudragit L30D-55 suspension was sprayed at an atomizing air pressure of 0.2-0.3 bar.
[0160] Dissolution of Adalimumab from the pellet A certain amount of adalimumab-loaded pellets was placed in a 5 ml cryotube and 4.0 ml of buffer was added to obtain a theoretical concentration of 1 mg / ml adalimumab based on the theoretically calculated loading amount of adalimumab. Citrate-TRIS buffer (pH 7) was used as the buffer. Samples were stirred throughout the experiment. Supernatant samples were taken at designated time points, centrifuged, and the supernatants were analyzed for total protein content. For enteric-coated pellets, pellets were first exposed to 0.1N HCl for 2 hours under continuous stirring. Then, after removing the liquid, citrate-TRIS buffer (pH 7.0) was added to the buffer step carried out as described above.
[0161] Quantification of total protein content (Bradford): Quantification of total protein was performed colorimetrically according to the Bradford method using the Coomassie Plus assay (Thermo Fisher Scientific). Briefly, 6.6 μl of sample was pipetted into the bottom of a 96-well plate, 200 μl of Coomassie Plus reagent was added, and mixed by shaking at 500 rpm for 30 seconds. The sample was then incubated at room temperature for 10 minutes. Afterwards, the absorbance at 595 nm (Tecan plate reader) was recorded and the blank was subtracted. Quantification was performed using a freshly generated standard curve.
[0162] result Adalimumab release from immediate and sustained release pellet cores The uncoated pellets of Example 1 rapidly disintegrated in citrate-TRIS buffer (pH 7), resulting in rapid and nearly complete adalimumab release within 1 hour, whereas adalimumab release from the uncoated pellets of Example 2 was sustained over the duration of the experiment. (Table 3) JPEG2024109837000003.jpg54147
[0163] Adalimumab release from delayed (enteric) release pellet cores Both batches of adalimumab pellets were coated with Eudragit L30D-55 dispersion. After 2 h in 0.1 N HCl, the coated pellets were completely acid resistant (no release of adalimumab). Upon exchange into citrate-TRIS buffer (pH 7) (to simulate small intestinal luminal pH), adalimumab release started (release: ≥5%). Example 3
[0164] The therapeutic effect of anti-TNFα antibodies after local administration was investigated in an IBD mouse model. Due to the species specificity of Ab-REW, which does not bind to mouse TNFα, a surrogate antibody (cV1q) was used, consisting of the variable domain of the cV1q antibody (Echtenacher et al., 1990) combined with a mouse IgG2a constant region. The T cell transfer model was chosen because the gene expression pattern in this model best reflects the gene expression changes in IBD (when compared to DSS- and TNBS-induced colitis) (te Velde et al., Inflamm Bowel Dis 2007; 13(3):325-30). The model is clinically characterized by progressive weight loss and loose stools. Regarding histopathology, inflammation extends from the cecum to the rectum, with infiltration of macrophages and moderate numbers of activated CD4 + It is accompanied by lymphocyte and mucin depletion and epithelial hyperplasia, leading to glandular elongation and mucosal thickening. Increased gene expression of TNFα, IFN-γ, IL-6, CCR1, CCR2, CCR5, CXC chemokine receptor 3 and their ligands has been reported (Nagaoka and Radi, Front Biosci 2012 June;1;4:1295-314).
[0165] From WT mice to immunodeficient mice, naive CD4 + We adoptively transferred T cells to induce colitis and induced transmural colitis in recipients. Briefly, T cells (CD44 - / CD62L + ) was collected and purified, and 0.5 x 10 6 RAG2 cells - / -Mice were injected intraperitoneally. T cell engraftment was confirmed on day 20. A rat / mouse chimeric monoclonal antibody of the IgG2a isotype (mouse homologue to human IgG1) specific for mouse TNFα was used for treatment (Echtenacher et al., J Immunol 1990; 145:3762-66).
[0166] The mice were divided into four groups as follows (n=5 for untreated mice, n=12 for all other groups). Group 1 was untreated mice. Group 2 was administered the vehicle intrarectally. Group 3 received IgG2a intrarectally. As a positive control, group 4 received IgG2a intraperitoneally.
[0167] Anti-TNFα treatment was initiated 21 days after T cell transfer, when animals had established colitis, and continued for 28 days. Animals receiving rectal administration (300 μg / day IgG2a or 200 μl vehicle) were treated daily, while animals receiving intraperitoneal injections of IgG2a were treated twice weekly. Endpoints were body weight, endoscopic score (days 14-49), histological score (day 49), and cytokines in the colon (day 49).
[0168] result: Mice in the untreated and IgG2a (ip, ir) treated groups maintained or continued to gain weight, whereas animals in the vehicle treated group steadily lost weight (Figure 1).
[0169] A significant decrease in endoscopy score and a decrease in histology score were observed in the IgG2a-treated groups (ir and ip) (see Figures 2 and 3). During endoscopy, colitis was scored on a scale of 0 to 4 (0: normal; 1: loss of vascularity; 2: loss of vascularity and fragility; 3: fragility and erosion; 4: ulceration and bleeding). The total histology score was the sum of the individual scores (0 to 4, respectively) for inflammation, edema, goblet cell depletion, and epithelial damage.
[0170] Intraperitoneal treatment with IgG2a resulted in the greatest reduction of cytokines in the colon, followed by intrarectal treatment with IgG2a (see Figure 4). Values shown are the average of data from the proximal, medial and distal colon.
[0171] In summary, the local treatment works in a mouse T cell transfer model, as shown by significant reductions in endoscopy scores, histology scores, cytokines in the colon, and reduced weight loss.
[0172] Example 4 Dose-response study of treatment of colitis in a mouse model of colitis In a dose-response study, a therapeutically effective dose of the cV1q-huFc surrogate antibody was evaluated rectally in a T cell-transferred IBD mouse model using Tg32-SCID mice (human FcRn transgenic mice). Due to the species specificity of Ab-REW, which does not bind to mouse TNFα, a surrogate antibody (cV1q-huFc) was used that consists of the variable domain of the cV1q antibody (Echtenacher et al., 1990) and the constant domain of Ab-REW. The light and heavy chain sequences of the surrogate antibody are shown in SEQ ID NOs: 12 and 13, respectively. Transfection of naive CD4 +Colitis was induced by adoptive transfer of T cells. Treatment with cV1q-huFc was initiated 14 days after the adoptive transfer and continued until day 42. Mice were either treated with daily intrarectal administration of cV1q-huFc (10, 30, 100 and 300 μg / mouse), daily intracecal administration (300 μg / mouse) or twice weekly intraperitoneal injection of 10 mg / kg (control). Dose-dependent improvements in total histological scores consisting of colonic inflammation (submucosa and muscularis / serosa), crypt damage, erosion, hyperplasia and edema were observed in the proximal and distal colon after rectal treatment (Figure 5). Intracecal treatment also resulted in a reduction in histological scores. Furthermore, decreases in colonic cytokines IL-6, IL-17A, KC, TNFα and MIP-2 were observed after both rectal and intracecal administration (Figure 6). This was evident in the case of IL-17A, KC, and MIP-2 after intracecal administration. In summary, local administration of TNFα inhibitors reduces inflammation in the colon.
[0173] Example 5 Systemic Exposure After Rectal Administration The study was performed in healthy mice and mice suffering from colitis to measure systemic exposure to cV1q-huFc after rectal administration. Tg32-SCID mice were exposed to 3% DSS-treated drinking water on days 0–5 to induce colitis. Healthy and diseased mice were treated rectally with a single dose (SD) or repeated doses (MD; 0.1 or 0.3 mg) of cV1q-huFc. Due to blood collection limitations, only three blood samples could be collected from each mouse (left eye, right eye, and distal end). Thus, each treatment group (n=10–14 mice) was divided into two subgroups (n=5–7 mice) for blood collection. Single-dose animals were administered cV1q-huFc antibody on day 10, when colitis was established, and blood samples were collected at 1, 4, and 24 h (subgroup 1) and 2, 8, and 48 h (subgroup 2) after administration. Mice receiving repeated doses of cV1q-huFc were given daily rectal doses on days 10-14. Blood samples were taken 24, 72, and 120 hours (subgroup 1) and 48, 96, and 144 hours (subgroup 2) after the first dose of cV1q-huFc on day 10, always just before the next dose. In parallel, two groups (healthy and diseased) received a single intravenous injection of 5 mg / kg cV1q-huFc. Blood samples were taken as for mice treated rectally with a single dose. Plasma samples were analyzed by Imperacer® Immuno-PCR.
[0174] Systemic exposure after rectal administration was very low compared to intravenous administration (Figure 7). It was slight but not significant in animals with colitic disease compared to healthy animals. A single dose of cV1q-huFc administered rectally resulted in a calculated systemic bioavailability of <0.01% when compared to dose-normalized exposure (AUC). No systemic accumulation over time was observed after 5 days of administration.
[0175] Example 6 Systemic exposure and tissue concentrations after intracecal administration Tissue concentrations and systemic exposure of cV1q-huFc were measured in healthy mice and in mice suffering from colitis after intracecal administration. Male Tg32-SCID mice were operated on. A cannula was placed from the cecum back between the scapulae, exposing the tip of the cecum which was fixed in place using sutures, wound clips, and tissue adhesive. After surgery, animals were administered buprenorphine (3 days) and Baytril (5 days) and allowed to recover for 2-4 weeks before being assigned to the study. On days 0-5, mice were exposed to drinking water treated with 3% DSS to induce colitis. Healthy and diseased mice were treated with a single dose (n=16 per group) or repeated doses (n=8 per group) of cV1q-huFc. A dose of 0.3 mg / dose was administered for healthy mice, while two dose levels (0.1 and 0.3 mg / dose) were tested in colitic mice. When dosing the animals, 0.1 mL of cV1q-huFc was administered via the cannula, followed by rinsing with 0.05 mL of saline to prevent the drug from remaining in the cannula and not reaching the cecum. Four mice were sacrificed at each time point, and colons and blood (plasma) were collected. For animals treated with a single dose, cV1q-huFc antibody was administered on day 10, when colitis was established, and animals were sacrificed 1, 4, 8, and 12 hours after administration. For mice treated with repeated doses of cV1q-huFc, the antibody was administered intracecally daily on days 10-14, and animals were sacrificed 24 and 120 hours after the first dose of cV1q-huFc on day 10. In parallel, the two groups in which colitis was induced received single or repeated rectal administrations of cV1q-huFc at 0.3 mg / dose. Blood (plasma) samples were collected as for animals treated with intracecal administration. Plasma samples were analyzed by Imperacer® Immuno-PCR. At the time of sacrifice, colons were excised, rinsed, weighed, and trimmed to a length of 5 cm. 1 cm segments from both the proximal and distal ends were flash frozen for analysis by ELISA.
[0176] Plasma concentrations measured after intracecal administration were highly variable, as already observed after rectal administration. Systemic exposure (AUC) was increased by approximately 60-fold (single dose) or 200-fold (repeated dose) after intracecal administration compared to rectal administration, but overall systemic exposure was still very low (Figure 8). After 5 days of administration, a slight accumulation of cV1q-huFc in plasma was observed in most groups. Similar to plasma concentrations, levels of cV1q-huFc in tissues were highly variable within groups and between time points. Both intracoccygeal and intrarectal administration routes resulted in measurable antibody concentrations in the proximal and distal colon (Figure 9). In contrast to systemic exposure, where clear differences were observed between rectal and intracecal treatments, levels in tissues were comparable for both administration routes. No significant differences were observed between healthy and sick animals. Repeated administration for 5 consecutive days resulted in a slight accumulation of cV1q-huFc in the proximal and distal colon in most groups.
[0177] Example 7 Nivolumab-stimulated human CD4 + Effects on T cells Immune checkpoint inhibitors targeting PD-1 or CTLA-4 are highly effective cancer treatments, but are associated with several severe immune-related adverse events, such as colitis. Therefore, we investigated the effect of nivolumab-stimulated human CD4+ cells on IFNγ secretion in mixed lymphocyte reactions (MLRs). + The effect of Ab-REW on T cells was examined. As shown, nivolumab significantly increased CD4 T cells compared to untreated cells. +Nivolumab induces high levels of IFNγ secretion from T cells. Co-incubation of nivolumab with Ab-REW or infliximab inhibited IFNγ secretion in a dose-dependent manner, although considerable variability was observed between different donor pairs and runs (Figure 10). However, this trend was consistent between runs and donor pairs, indicating that this is a true biological phenomenon. Donor pairs capable of secreting higher levels of IFNγ did not appear to respond as strongly as donor pairs showing lower IFNγ secretion, suggesting that donor variability and strength of initial stimulation influence the efficacy of anti-TNFα agents in this setting. Interestingly, IC 50 The values were generally lower for Ab-REW (range 0.028–0.266 μg / mL) than for infliximab (range 0.068–0.326 μg / mL), suggesting that Ab-REW may be a more potent inhibitor of nivolumab-mediated IFNγ secretion than infliximab.
Claims
1. The present invention relates to an antibody specific for tumor necrosis factor alpha (TNFα) and a Fab fragment, F(ab') for the treatment or prevention of at least one adverse event of the gastrointestinal tract induced by one or more immune checkpoint (ICP) inhibitors induced by cancer therapy in a patient. 2 1. A pharmaceutical composition comprising an active agent selected from the group consisting of functional fragments and derivatives thereof including antibody fragments, Fab' fragments, scFv, dsFv, bispecific antibodies, triabodies, tetrabodies, Fc fusion proteins, camelid antibodies, VHHs, VNARs, and minibodies, wherein said treatment or prevention comprises local administration of said composition to the ileum and / or large intestine of said patient, said patient being a cancer patient, and said patient also receiving treatment with one or more ICP inhibitors, wherein treatment with the one or more ICP inhibitors has been discontinued for less than four weeks.
2. The pharmaceutical composition of claim 1 , wherein the treatment is not interrupted.
3. 3. The pharmaceutical composition of claim 1 or 2, wherein the adverse event is selected from the group consisting of ICP inhibitor-induced diarrhea, ICP inhibitor-induced colitis, ICP inhibitor-induced enterocolitis, and combinations thereof.
4. 4. The pharmaceutical composition of claim 3, wherein the ICP inhibitor-induced diarrhea, colitis, and / or enteritis is characterized by first- or second-grade toxicity.
5. 4. The pharmaceutical composition of claim 3, wherein the treatment prevents the progression of the ICP inhibitor-induced diarrhea, colitis, and / or enteritis to higher grade toxicity.
6. The pharmaceutical composition according to any one of claims 1 to 5, wherein the prevention comprises prophylactic treatment of ICP inhibitor-induced diarrhea, colitis, and / or enteritis.
7. The pharmaceutical composition of claim 6, wherein the patient is concurrently undergoing treatment with one or more ICP inhibitors.
8. The pharmaceutical composition according to any one of claims 1 to 7, wherein the patient is suffering from ICP inhibitor-induced diarrhea but not suffering from ICP inhibitor-induced colitis or ICP inhibitor-induced enteritis, and the composition is for preventing the progression or onset of ICP inhibitor-induced colitis and / or ICP inhibitor-induced enteritis in the patient.
9. The pharmaceutical composition of claim 8, wherein the patient is suffering from ICP inhibitor-induced diarrhea of secondary toxicity.
10. The pharmaceutical composition of claim 8, wherein the patient is suffering from ICP inhibitor-induced diarrhea of class 1 toxicity.
11. 11. The pharmaceutical composition of any one of claims 1 to 10, wherein the one or more ICP inhibitors are selected from the group consisting of an antibody specific for cytotoxic T-lymphocyte-associated protein-4 (CTLA-4), an antibody specific for programmed cell death protein-1 (PD-1), and an antibody specific for programmed death ligand 1 (PD-L1).
12. 12. The pharmaceutical composition of claim 11, wherein the antibody specific for PD-1 is selected from the group consisting of pembrolizumab and nivolumab; the antibody specific for PD-L1 is selected from the group consisting of atezolizumab, avelumab, and durvalumab; or the antibody specific for CTLA-4 is selected from the group consisting of ipilimumab and tremelimumab.
13. The pharmaceutical composition according to any one of claims 1 to 12, wherein the antibody or functional fragment thereof specific for TNFα is selected from the group consisting of infliximab, adalimumab, etanercept, certolizumab pegol, golimumab, and functional fragments and derivatives thereof.
14. The amino acid sequence of the heavy chain of the TNFα-specific antibody or functional fragment thereof is i) a deletion of amino acids 233P, 234V, 235A and at amino acid position 236; and amino acid 434A or amino acids 252Y, 254T and 256E; and optionally also amino acids 239D, 330L and 332E or amino acids 326A, 332E and 333A; and / or ii) amino acids 380A and 434A, and optionally amino acid 307T; and / or iii) amino acid 434W, and optionally amino acid 428E and / or amino acid 311R (Herein, the amino acid numbering refers to EU numbering.) The pharmaceutical composition according to any one of claims 1 to 13, comprising:
15. The pharmaceutical composition according to any one of claims 1 to 14, wherein said topical administration comprises or consists of oral administration of said pharmaceutical composition.
16. 16. The pharmaceutical composition of claim 15, wherein the pharmaceutical composition is a delayed release formulation.
17. 17. The pharmaceutical composition of claim 15 or 16, wherein the pharmaceutical composition is a solid dosage form in the form of pellets, granules, microparticles, nanoparticles, minitablets, spheres, capsules, tablets, or a multiparticulate drug delivery system coated with a delayed release coating that prevents release of the active agent before entering the ileum, ileocolic region or large intestine of the gastrointestinal (GI) tract.
18. The delayed release coating is selected from the group consisting of polyvinyl acetate phthalate, cellulose acetate trimellitate, hydroxypropyl methylcellulose phthalate HP-50, HP-55 or HP-55S, cellulose acetate phthalate, hydroxypropyl methylcellulose acetate succinate (HPMCAS), poly(methacrylic acid, ethyl acrylate) 1:1, poly(methacrylic acid, methyl methacrylate) 1:1, poly(methacrylic acid, methyl methacrylate) 1:2, chondroitin sulfate, pectin, glycerol ...
18. The pharmaceutical composition of claim 17, comprising at least one component selected from the group consisting of arginum, chitosan, inulin, lactulose, raffinose, stachyose, alginate, dextran, xanthan gum, locust bean gum, arabinogalactan, amylose, cyclodextrin, pullulan, carrageenan, scleroglucan, chitin, curdlan, levan, amylopectin, starch, resistant starch, azo compounds decomposed by azo bond-decomposing bacteria, and combinations thereof.
19. The pharmaceutical composition according to any one of claims 15 to 18, comprising a sustained release coating or a sustained release matrix.
20. 20. The pharmaceutical composition of claim 19, wherein the sustained release coating or matrix comprises a material that disintegrates over time.
21. 21. The pharmaceutical composition of claim 20, wherein the time-disintegrating material is selected from the group consisting of poly(ethyl acrylate, methyl methacrylate) 2:1; poly(ethyl acrylate, methyl methacrylate, trimethylammonioethyl methacrylate chloride) 1:2:0.1; ethyl cellulose; poly(ethyl acrylate, methyl methacrylate, trimethylammonioethyl methacrylate chloride) 1:2:0.2; polyvinyl acetate; and combinations thereof.
22. The pharmaceutical composition of any one of claims 15 to 21, wherein the composition comprises a sustained release core coated with a delayed release coating.
23. The pharmaceutical composition according to any one of claims 15 to 21, wherein the composition comprises a core, a sustained release coating, and a delayed release coating.
24. The pharmaceutical composition according to any one of claims 1 to 14, wherein said treatment comprises rectal administration of said composition.
25. 25. The pharmaceutical composition of claim 24, wherein the composition is an enema solution, gel, foam, or suppository.
